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Colorectal cancer (CRC) is the third most common cancer in the United States. 
Approximately 90% of colon cancer deaths arise from cancer metastasis, the process by 
which primary tumors invade into and start to proliferate in a distant new site. Dietary 
factors are closely associated with development and progression of colon cancer. 
Genistein, one of the major phytochemicals in soy, has been shown to suppress 
metastasis in different cancer types including colon cancer. Moreover, studies have 
indicated that genistein is a mediator of epigenetic regulations, including DNA 
methylation and histone modifications, both in vitro and in vivo.  But there is lack of 
critical data indicating the epigenetic mechanisms of metastasis prevention potentials of 
genistein. 
Because of the known functions of genistein in the suppression of cancer metastasis 
and its epigenome-modifying capabilities, we hypothesized that genistein can repress 
colon cancer metastasis, which involves epigenetic regulation. 
To test our hypothesis, first of all, the role of epigenetic regulation in colon cancer 
metastasis was investigated. Our research was focused on the study of metastasis 
suppressor, a type of molecules that inhibit cancer metastasis, in cell model SW480 and 
SW620.  SW480 and SW620 are two colon cancer cell lines established from the same 
patient with different metastatic potentials, making them an ideal model for investigation 
of metastatic mechanisms.  N-Myc downstream-regulated gene 1 (NDRG1) is known as a 
metastasis suppressor. We showed that NDRG1 mRNA in primary colon cancer cell line 
SW480 was forty times higher than that in highly metastatic SW620. Knockdown of 
NDRG1 in SW480 to a level that is similar to that in SW620 also modulated cell cycle 
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and proliferation in SW480 towards the status of the highly metastatic SW620. Both 
DNA methylation and histone modification of NDRG1 in SW480 and SW620 were 
tested.  We found that the silencing of NDRG1 in SW620 was not due to promoter 
hypermethylation. Chromatin immunoprecipitation revealed gene-wide decrease in 
histone H4 acetylation (H4Ac) and increase in phosphorylated histone H3 serine 10 
(pH3S10) at the NDRG1 promoter in SW620. Meanwhile, the NDRG1 coding region 
showed much higher histone H3 lysine 4 methylation (H3K4me2) in SW480. These 
unique histone modifications in two colon cancer cell lines with different metastatic 
potentials suggested metastasis suppressor NDRG1 was epigenetically regulated in 
metastatic colon cancer cell line. 
In addition to NDRG1, dramatic down-regulation of Wnt5a, one of the WNT 
signaling factors, was also found in SW620 compared to SW480. Wnt5a expression was 
not responsive to DNA methyltransferase inhibitor 5-aza-cytidine treatment.  However, 
histone deacetylase (HDAC) inhibitors trichostatin A (TSA) and sodium butyrate (NaBt) 
both significantly increased the mRNA expression of Wnt5a in SW620. NaBt treatment 
increased β-catenin signaling and diminished the difference in cell adhesion ability 
between SW480 and SW620, suggesting that the HDAC inhibitor plays critical roles in 
Wnt signaling pathway and cell physiology that relate to metastasis. Importantly, the 
lower transcription of Wnt5a in SW620 than SW480 corresponded to multiple histone 
modifications, including lower levels of acetylated histone H3 and H4 (H3Ac and H4Ac), 
dimethyl H3 lysine 4 (H3K4me2), and higher levels of trimethyl H3 lysine 27 
(H3K27me3) in the promoter region. These results suggested the importance of Wnt5a in 
colon cancer metastasis and also indicated that the silencing of Wnt5a in the highly 
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invasive human colon cancer cell line might result from transcriptional regulation of the 
gene by histone modifications. 
With the above findings, which indicated that epigenetic regulation of metastasis 
suppressor genes (specifically NDRG1 and Wnt5a) played an important role during colon 
cancer metastasis, next we tested the hypothesis that genistein represses colon cancer 
metastasis in vitro by modifying the expression of metastasis suppressor NDRG1 via 
epigenetic regulation. Genistein treatment extensively changed cellular properties of 
SW480 and SW620. For example, Genistein reduced the proliferation and migration of 
both cell lines. Genistein specifically increased the adhesion of the metastatic cell line 
SW620, which was correlated to increased expression of E-cadherin and the decrease of 
matrix metalloproteinases-7 (MMP-7). Moreover, genistein increased the mRNA 
expression of NDRG1. The enhanced NDRG1 gene expression in SW620 was associated 
with increased gene transcription activity and altered histone structure of the gene. 
H3K36me3, a positive histone modification, was increased by genistein at 5’untranslated 
region (5’UTR) and distal downstream regions. Genistein also caused global decrease of 
H3S10p in both cell lines. 
The following study aimed at investigating the effect of genistein on liver metastases 
derived from colon cancer and the molecular mechanism behind in an in vivo model. 
Male athymic nude mice were fed with western diet (W; calories%, fat 39%, carb 50%), 
W diet supplemented with 100ppm Gen (GL) or 500ppm Gen (GH) . After 16 weeks, all 
the animals were intrasplenically injected with metastatic human colon cancer cells 
SW620 and sacrificed 8 weeks later. GL and GH mice showed lower % liver metastases 
(50% and 27.3%) compared to W group (80% of mice with metastases). Pathological 
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evaluations of representative liver sections from all animals showed no significant 
differences of liver metastases derived from injected SW620, such as metastases size, % 
of necrosis and mitotic index. mRNA expressions of metastasis-related human genes 
tested by real-time PCR also showed no difference of gene expression. Only the 
proliferation index represented by pH3S10 positive cells in liver metastases in W group 
was higher than GL and GH groups. Intriguingly, the expression of both β-catenin (key 
intracellular mediator of the Wnt signaling pathway) and NDRG1 were increased by 
dietary genistein in normal liver sections, suggesting the liver microenvironment was 
altered by genistein, which might be highly responsible for the lower metastasis 
incidence in liver in genistein treatment group. 
The results of this study for the first time demonstrated the anti-metastatic function of 
genistein in colon cancer metastasis both in vitro and in vivo. Epigenetic regulation, 
especially histone modification, was shown to play an important role in colon cancer 
metastasis through regulating the expression of metastasis suppressor genes in our study. 
The findings from our study increase the understanding of the anti-metastatic effect of 
genistein in colon cancer metastasis and provide important information for applying 
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Cancer metastasis is secondary to cancer development and yet it accounts for most 
cancer death.  Metastasis is the process by which primary tumors invade into and start to 
proliferate in a distant new site.  Simply, it involves the migration of primary tumors 
through the tumor stroma, intravasation into the vasculature, followed by the last step of 
“colonization” [1].  Despite the recent and continuous improvements on diagnosis and 
treatments, more than 50% of colon and rectal cancers metastasize to liver, lung, and 
lymph nodes [2].  Five year survival rate remains below 50% for patients with metastatic 
colon cancer.  Because cancer metastasis is one of the major steps in cancer development, 
it is subject to intense investigations for the prevention and treatment of cancer.  
Efforts have been made to identify metastasis suppressor genes (MSG), which encode 
proteins responsible for inhibiting the metastasis but not suppressing the growth of 
primary tumors.  NDRG1 (also known as cap43/rit42/RTP/Drg1/TDD5) has been shown 
to inhibit cancer metastasis, including prostate, breast and colon cancer [1, 3-5].  A 
clinical study has shown that lower NDRG1 mRNA expression was correlated with 
shorter 5-year survival in colon cancer patients [6].  It was reported that over-expression 
of NDRG1 in metastatic colon cells suppressed their invasiveness up to 70% through 
inhibition of cell differentiation [3].  Athymic mice, when injected with invasive human 
colon cancer cell SW620 that is overexpressing NDRG1, had only 23% of liver 
metastases, compared to 75% in the control group [3].  More importantly, it has been 
proposed that NDRG1 expression is regulated by DNA methylation and histone 
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modifications [7], which are the two main epigenetic mechanisms.  Promoter region of 
human NDRG1 cDNA contains multiple CpG site, suggesting that transcription of 
NDRG1 can be regulated by DNA methylation.  The expression of NDRG1 was also 
upregulated by histone deacetylase inhibitors [3, 8].  Our most recent study suggested 
that histone modifications could provide a critical mechanism of NDRG1 repression 
during colon cancer metastasis [8].   
 Unlike NDRG1, Wnt5a, one of the Wnt proteins that make up the family of secreted 
lipid-modified glycoproteins, is paradoxical regarding its function in cancer development. 
Wnt5a may have a tumor -suppressing or –promoting effect depending on the cancer type 
[9]. For example, loss of Wnt5a expression is associated with increased colon cancer and 
breast cancer metastasis [10, 11]. However, high Wnt5a expression is related to poor 
melanoma prognosis [12] and contributes to gastric cancer cell aggressiveness [13]. In 
addition, Wnt5a expression can also be regulated by both DNA methylation and histone 
modification [14, 15]. 
 Genistein, a soy isoflavone, has been shown to suppress metastasis in different 
cancer types, including prostate cancer [16], breast cancer [17], and colon cancer [18].  
Genistein decreased bone and liver metastases in nude mice injected with green 
fluorescent protein (GFP) tagged MDA-MB-435 cells [19], which is a highly metastatic 
human breast carcinoma cell line.  Genistein also reduced lung metastasis of murine 
colon cancer cells by 44% [18].  These preclinical findings have been supported by early 
clinical trials, in which subjects administered genistein showed decreased markers of 
advanced metastatic disease [20].  Recent studies showed that genistein mediates 
alterations of histone acetylation as well as DNA methylation of various genes in cancer 
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cell lines [21-23].  Demethylation of CpGs, inhibition of Dnmts and MBD2 activity, and 
activation of the histones by acetylation and demethylation at the BTG3 promoter 
followed by genistein treatment were observed in renal cancer cells [23].  In animal 
models, dietary genistein intake has been shown to induce alteration of epigenetic 
patterns in rats and mice [24].   
Because of the reported anti-metastatic functions of genistein in malignant cancers 
and its epigenome-modifying capabilities, the objective of this study was to investigate 
the effect of genistein on colon cancer metastasis through epigenetically regulating 


































Cancer metastasis and metastatic patterns 
      The metastatic cascade describes the process where neoplastic cells in a primary 
tumor leave their initial location of growth, travel to nearby or distant secondary sites and 
proliferate into a macroscopic, clinically relevant mass. The process involves intrinsic 
(i.e., genetic) as well as extrinsic (i.e., tumor cell–microenvironmental signals) factors 
[25]. 
      Understanding the distribution patterns of distant metastases from primary tumors has 
been both a therapeutic challenge and an intellectual challenge for more than 100 years. 
Two prevailing hypotheses to explain the metastatic patterns are the mechanical or 
hemodynamic hypothesis and the seed-and-soil hypothesis [26, 27]. The mechanical 
hypothesis focuses on the anatomic delivery system: spread of the tumor first into the 
lymphatic system or body cavity followed by distant spread through the venous system 
[26]. Because organ drainage routes are invoked to explain metastatic patterns, it follows 
that tumors with different drainage routes should exhibit different metastatic patterns. 
However, venous drainage and other blood flow patterns do not help predict all distant 
metastatic sites. Stephen Paget proposed the seed-and-soil hypothesis and described the 
distribution of distant metastases from a primary tumor as a plant that goes to seed: Its 
seeds are carried in all directions, but they can live and grow only if they fall on 
congenial soil [28]. However, he also suggested that there was more to the patterns of 
metastasis than factors that involved arterial flow or blood supply. The seed-and-soil 
hypothesis is challenged by emerging microarray data, which suggest that tumor cells 
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may be programmed early on and that organ-specific metastatic gene expression 
signatures that are superimposed in the parent tumor also may account for the various 
patterns observed [29]. 
The high level of complexity of metastasis pattern is inevitably related to the 
interactions of tumor cells and microenvironment, which are crucial at many steps 
throughout the metastatic process. Cancer cells are not only dependent on genetic 
alterations that distinguish them from their normal counterparts, but are also sensitive to 
extracellular factors that may or may not allow them to metastasize [25]. Tumor cells 
alter the microenvironment directly (e.g., proteolytic cleavage of the ECM) or indirectly 
(e.g., induction of nearby cells to secrete proteases) [30] 
 The development of liver metastasis of colon cancer is, like many other types of 
cancer metastasis, the result of a sequence of events that cancer cells pass through 
successfully. First, tumor cells acquire motility through a transforming process called 
epithelial mesenchymal transition (EMT), and break through the basement membrane 
into surrounding tissues. Second, the transformed cells invade into local blood vessels 
that lead to a major portal vein, and survive in the blood stream. Third, the survived cells 
settle in liver parenchyma. Finally, cancer cells that settle in a new environment restart 
proliferation to form a metastic foci [31] For successful formation of metastatic foci in 
the liver, the final two steps of metastasis seem challenging, because the cells must adapt 
to the harsh microenvironment of the liver. On the other hand, the former steps seem 
relatively easy to be overcome due to direct blood circulation via portal veins and the 
porous nature of liver sinusoids [32]. Therefore, the biological mechanisms by which the 
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metastatic cells settle and proliferate in liver, as well as the roles of cancer cells and liver 
microenvironment in colon cancer metastasis are of particular interest in our study.  
Epigenetic changes and cancer 
 
        Genetics alone cannot completely explain the development and progression of 
cancer, and it is now understood that epigenetic abnormalities, in addition to genetic 
alterations, are involved in tumorigenesis and metastasis [33, 34]. Epigenetics, the 
heritable changes in gene expression that are not caused by DNA sequence alterations, 
include DNA methylation, histone modifications and microRNAs [35, 36]. DNA 
methylation occurs at cytosine residues in cytosine-guanine (CpG) dinucleotides and is 
controlled by DNA methytransferases (DNMTs). CpG sites are mainly distributed in 
CpG-rich regions, known as CpG islands. Most CpG islands are located in repetitive 
elements, such as centromeres, microsatellite sequences and the proximal promoter 
regions of approximately half of the genes in the genome of normal cells, where the 
islands are generally unmethylated  [37, 38]. The transcriptional inactivation of tumor 
suppressor genes by CpG island promoter DNA hypermethylation is well-known as one 
of the alterations that contributes to tumorigenesis in cancer cells [35]. It is also 
speculated that this global DNA hypomethylation contributes to tumorigenesis by causing 
chromosomal instability or the reactivation of transposable elements [35, 39]. 
 In addition to DNA methylation, histone modifications are epigenetic marks that are 
involved in chromatin structure and gene expression. Histone modifications refer to 
covalent modifications of histone tail residues, which affect gene expression by 
regulating the access of transcriptional machinery to coding sequence [40]. Histone 
modifications occur at the amino acid tails of 4 core histones, i.e.H2A, H2B, H3, and H4. 
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They are reversible and post-translational modifications, including acetylation, 
methylation, phosphorylation, ADP-ribosylation, ubiquitination, sumoylation, and 
biotinylation [41]. One well-studied histone modification is methylation, which occurs on 
either arginine or lysine residues and can result in either transcriptional activation or 
repression depending on the residue and number of methyl groups added [42]. For 
example, the trimethylation of histone H3 lysine 9 (H3K9me3), H3 lysine 27 
(H3K27me3), H3 lysine 36 (H3K36me3) and H4 lysine 20 (H4K20me3), in addition to 
H3K9 dimethylation (H3K9me2), facilitates transcriptional repression, whereas the 
trimethylation of H3 lysine 4 (H3K4me3) is associated with transcriptional activation 
[41]. Another common histone modification is acetylation of lysine residues on histone 
H3 and H4, which is primarily controlled by histone acetyltransferases (HATs) and lead 
to open chromatin structure with transcriptional activation; whereas histone 
hypoacetylation, catalyzed by HDAC, induces a closed DNA structure and lead to 
repressed transcription [43]. 
  Histone modifications play important roles in regulating gene expression during 
cancer development. Many studies have shown variations in global levels of histone 
marks in different grades and phenotype classes of various cancer types. For example, 
Elsheikh et al. [44] observed low or absent acetylated histone H4 at lysine 16 in the 
majority of breast cancer cases (78.9%), suggesting that this alteration may represent an 
early sign of breast cancer. For prostate cancer, dynamic changes of H3K4me3 or 
H3K27me3 were found to be correlated with changes of gene expression during epithelial 
to mesenchymal transition (EMT) [45].  The transcriptional silencing of tumor-
suppressor genes in cancer cells is reported to be associated with a loss of active histone 
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marks and a gain of repressive marks [38]. Specifically, H3K9/14ac at 29 genes was 
increased in breast cancer cells. The functions of these genes are associated with 
regulation of apoptosis, programmed cell death, nuclear lumen, DNA damage checkpoint, 
mitotic cell cycle, and small conjugating protein ligase activity [46]. During 
accumulation of malignant features in prostate cancer, complete loss of H3K4me3 was 
accompanied with full silencing of E-cadherin expression [45]. 
       Histone modification, which has recently been used as an epigenetic cancer therapy, 
aims to restore normal chromatin modification patterns through regulating epigenetic 
machinery. Histone deacetylase inhibitors represent the first putative epigenetic therapies. 
More recently, drugs that inhibit histone methyltransferases were developed. However, 
these agents have pleiotropic effects and it remains unclear how they lead to therapeutic 
responses [47]. Thus, understanding the mechanism of histone modification in cancer is 
essential to the develop pment of epigenetic cancer therapies. 
Metastasis Suppressor  
Metastasis suppressors (MS) are molecules that inhibit the process of metastasis 
without preventing growth of the primary tumor. By now, over 20 MS have been 
confirmed in vivo. Some MS can only inhibit the metastatic progress of one type of 
cancer, while others can suppress the metastasis in a variety of cancers. The mechanisms 
of MS are diverse, ranging from cell adhesion alteration, apoptosis induction to 
transcription regulation [48].   
NDRG1 (also known as cap43/rit42/RTP/Drg1/TDD5) has been shown to inhibit 
cancer metastasis, including prostate, breast and colon cancer [1, 3, 7, 49]. It was reported 
that over-expression of NDRG1 in metastatic colon cells suppressed their invasiveness up 
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to 70% through inhibition of cell differentiation [3]. Lower NDRG1 mRNA expression 
was correlated with shorter 5-year survival in colon cancer patients [6]. Athymic mice, 
when injected with invasive human colon cancer cell SW620 which was over-expressed 
with NDRG1, had only 23% of liver metastases, compared to 75% in the control group 
[3]. We found that knocking down of NDRG1 expression in non-invasive human colon 
cell line SW480 reduced the proliferative rate and adhering ability of SW480 to the level 
that is similar to the highly invasive cell line SW620 [8], suggesting that NDRG1 affects 
adhesion of colon cancer cells. 
 More importantly, it has been proposed that NDRG1 expression is regulated by DNA 
methylation and histone modifications.  Promoter region of human NDRG1 cDNA 
contains multiple CpG sites, suggesting that transcription of NDRG1 can be regulated by 
DNA methylation.  The transcription of NDRG1 can be induced by DNA methylation 
inhibitor 5-aza-C in a dose-dependent manner, indicating that DNA methylation regulates 
NDRG1 expression [3, 8]. However, bisulfite sequencing of a putative CpG island at the 
promoter region of the human NDRG1 gene revealed that there is minimal CpG 
methylation in both SW480 and SW620, suggesting that the region tested for DNA 
methylation (-770/-250) may not represent the regulatory region for DNA methylation 
[8]. 
The expression of NDRG1 was also up-regulated by histone deacetylase inhibitors [3, 
8].  Our most recent study suggested that histone modifications, mainly via acetylated H4 
and methylated H3K4, could provide a critical mechanism of NDRG1 repression during 
colon cancer metastasis [8].   
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E-cadherin is another MS downregulated in CRC metastases. E-cadherin (encoded by 
CDH1 gene) is a member of Ca2+-dependent adhesion molecules and is critical for 
maintaining tissue structure by regulating intercellular contacts [50]. It is generally 
accepted that strongly expressed E-cadherin is present in cancers with tight cell-cell 
adhesion and weak invasiveness; however, reduced expression of E-cadherin is 
commonly observed in cancers with weak cell-cell adhesion and higher invasiveness. For 
example, E-cadherin expression was inversely correlated with higher stage and lymph 
node metastases of CRC as examined by immunohistochemistry or in situ hybridization 
[51]. In addition to the well-known function of E-cadherin in cell-cell and/or cell-matrix 
adhesion, the expression of E-cadherin is inversely correlated to the quantity of migrating 
colon cancer cell lines, suggesting E-cadherin also regulates colon cancer cell migration 
[52]. Regulation of E-cadherin expression by epigenetic modifications has been reported 
by many groups. Hypermethylation has been shown to be a major contributor to the 
decreased E-cadherin expression. Garinis et al. examined the methylation status of the E-
cadherin promoter by methylation-specific polymerase chain reaction (MSP) in sporadic 
colorectal carcinomas and they observed a significant inverse association between the E-
cadherin methylated alleles and E-cadherin mRNA level [53]. Darwanto et al. proposed 
that expression of methyl-CpG-binding protein (MeCP) 2, which acts as a transcriptional 
repressor by non-specifically binding to methyl-CpGs and promoter methylation 
cooperatively regulate the expression of E-cadherin in colon cancer [54]. Kao et al. tested 
the methylation of 33 CpG sites in the CDH1 promoter region in six human cancer cell 
lines by bisulfite sequencing [55]. CpG sites in the CDH1 promoter were completely 
methylated in cell lines expressing E-cadherin, i.e., Lu-135, HeLa and HL-60. However, 
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CDH1 was almost completely unmethylated in H358, HT-29 and MKN74, which do not 
express E-cadherin. 
To understand how the metastasis suppressors are epigenetically regulated during 
colon cancer metastasis is of particular interest in our study.  
Dietary genistein and colon cancer  
Genistein, a soy isoflavone, has been shown to suppress metastasis in different cancer 
types, including prostate cancer [16], breast cancer [17], and colon cancer [18].  
Genistein decreased bone and liver metastases in nude mice injected with green 
fluorescent protein (GFP) tagged MDA-MB-435 cells [19], which is a highly metastatic 
human breast carcinoma cell line.  Genistein also reduced lung metastasis of murine 
colon cancer cells by 44% [18].  These preclinical findings have been supported by early 
clinical trials, in which subjects administered genistein showed decreased markers of 
advanced metastatic disease [20].  Genistein has been shown to inhibit cancer metastasis 
due to its ability to regulate nearly every step of the metastatic cascade, including cell 
adhesion, migration, invasion and angiogenesis [20, 56]. The effect of genistein on 
metastatic cascade involves many MS or related signaling pathways, such as E-cadherin, 
MMP, NF-kappaB [20].  
      Genistein mediates alterations of histone acetylation as well as DNA methylation of 
various genes in cancer cell lines [21-23, 57]. One of our studies showed that the time-
dependent induction of WNT5a by genistein in colon cancer cell line SW1116 was 
correlated with decreased methylation of a CpG island within its promoter as determined 
by bisulfite sequencing [57]. Demethylation of CpGs, inhibition of Dnmt and MBD2 
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activity, and activation of the histones by acetylation and demethylation at the BTG3 
promoter followed by genistein treatment were observed in renal cancer cells [23]. In 
animal models, dietary genistein intake has been shown to alter epigenetic patterns in rats 
and mice [24, 58]. Using the mouse differential methylation hybridization array, 
alteration of DNA methylation in specific genes in mice was observed following feeding 
of a genistein containing diet compared to that in mice fed a control casein diet [24]. 
Other direct evidence that genistein affected DNA methylation was that maternal 
exposure to dietary genistein altered the epigenome of offspring in viable yellow agouti 
(Avy/a) mice. Overall, the potential of genistein as an effective epigenome modifier, 
which may greatly impact CRC metastasis, highlights the potential ability of dietary 
genistein to improve CRC prognosis. 
In summary, there is a potential role for dietary genistein in preventing colon cancer 
metastasis through epigenetic regulation; however, the specific mechanism needs to be 
studied. Therefore, the overall objective of this study was to evaluate dosage, duration 
and mechanism of the anti-metastasis potential of dietary genistein in vitro and in vivo 
models. We expect that the results of this research will provide a better understanding of 
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CHAPTER 3 
Transcriptional silencing of N-Myc downstream-regulated gene 1 (NDRG1) in 





N-Myc downstream-regulated gene 1 (NDRG1) plays vital roles in tumor metastasis 
suppression and it is frequently silenced in metastatic colon cancers. NDRG1 is silenced 
in a highly metastatic colon cancer cell line SW620. The objective of this study was to 
investigate the potential mechanisms involved in silencing of the NDRG1 gene. SW480 
and SW620 are two colon cancer cell lines established from the same patient with 
different metastatic potentials, making them an ideal model for investigation of metastatic 
mechanisms.  Knockdown of NDRG1 in SW480 to a level that is similar to that in 
SW620 also modulated cell cycle and proliferation in SW480 towards the status of the 
highly metastatic SW620. Epigenetic mechanisms of the transcriptional control of 
NDRG1 were investigated. The silencing of NDRG1 in SW620 was not due to promoter 
hypermethylation as bisulfite sequencing of the NDRG1 promoter showed minimal DNA 
methylation in both cell lines. On the other hand, chromatin immunoprecipitation showed 
a significantly higher level of RNA polymerase II (Pol II) association with the NDRG1 
promoter in SW480 compared to SW620, in agreement with its gene expression level. 
The low Pol II binding at the NDRG1 promoter in SW620 was associated with gene-wide 
decrease in histone H4 acetylation (H4Ac) and increase in histone H3 serine 10 
                                                          
1This chapter is based on our published paper “Li Q, Chen H. Transcriptional silencing of N-Myc 
downstream-regulated gene 1 (NDRG1) in metastatic colon cancer cell line SW620. Clin Exp Metastasis. 
2011 28(2):127-35.”  
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phosphorylation (H3S10p). Meanwhile, the NDRG1 coding region showed much higher 
histone H3 lysine 4 methylation (H3K4me2) in SW480. In conclusion we observed 
unique histone modifications in two colon cancer cell lines with different metastatic 
potentials, indicating possible mechanisms for the down-regulation of NDRG1 in 
metastatic SW620.  
Introduction  
Colon cancer is one of the most common cancers, and mortality from colon cancer 
primarily results from its metastasis. Tumor metastasis involves the migration of primary 
tumor cells through the physical boundaries, after which they can disseminate and finally 
colonize in a distant organ [1, 59]. It is generally accepted that the development of 
metastasis can be caused by inactivation of DNA repair genes, such as metastasis 
suppressor [1], and abnormal epigenetic regulations [60].  
NDRG1 (also known as cap43/rit42/RTP/Drg1/TDD5) is a member of the NDRG 
gene family [1, 61, 62] and has been shown to play an important role in metastasis 
suppression [1, 3-5]. It was reported that over-expression of NDRG1 in metastatic colon 
cells suppressed their invasiveness [3]. Furthermore, a clinical study showed that lower 
NDRG1 mRNA expression was correlated with shorter 5-year survival in colon cancer 
patients [6]. In vitro studies have shown that NDRG1 functions in cell cycle inhibition 
[62, 63], cellular differentiation [3], and apoptosis [64], but the molecular mechanisms of 
NDRG1 as a metastasis suppressor still need to be elucidated. 
NDRG1 expression is controlled at the transcriptional level by multiple factors.  It 
has been shown that DNA damage induces NDRG1 expression in a p53-dependent 
manner [62]. Hypoxia up-regulates NDRG1 expression via hypoxia inducible factor-1 
- 15 - 
 
[65, 66]. The hypoxia signaling pathway is also involved in Egr-1-induced transcription 
of NDRG1 expression [67]. On the other hand, NDRG1 expression is repressed by two 
transcription factors N-Myc and c-Myc [68, 69]. Epigenetic control is another common 
mechanism to suppress tumor metastasis. Inhibition of DNA methylation and histone 
deacetylation activate NDRG1 expression [3], indicating that NDRG1 expression 
involves epigenetic regulation. The mechanisms involving epigenetic control in colon 
cancer metastasis are still unclear.  
In the present study, two human colon cancer cell lines derived from the same 
primary colon tumor, SW480 and SW620, were used as a model for analysis of 
involvement of NDRG1 in metastasis. SW480 was established from the primary tumor 
and SW620 from a lymph node metastasis in the same patient a year later [70]. SW480 
and SW620 are well characterized and represent the different features between primary 
and distinct metastatic sites [71], providing a unique model for studying epigenetic 
modifications in the background of the two cell lines. Our study indicated that NDRG1 
gives rise to certain physiological differences between colon cancer cell lines SW480 and 
SW620. Moreover, we report that chromatin modification is associated with the 
regulation of NDRG1 expression. 
Results  
NDRG1 is silenced in the highly metastatic cell line SW620 
Real-time RT-PCR and western blotting were performed to measure the mRNA 
expression and protein level of NDRG1, respectively, in both SW480 and SW620. 
Results showed that the NDRG1 mRNA in SW480 was forty times higher than that in 
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SW620 (Figure 3.1a), and that the NDRG1 protein (Figure 3.1b) was consistent with the 
relative mRNA level in the two cell lines.  
Knockdown of NDRG1 by small interfering RNA (siRNA) in SW480 shifted cellular 
profile toward the phenotype in SW620  
To investigate the effects of NDRG1 gene expression on cellular properties of 
SW480, siRNA targeting NDRG1 was transfected into both SW480 and SW620. The 
mRNA and protein levels were tested using quantitative real-time RT-PCR and western 
blotting, respectively. Results showed that siRNA effectively reduced NDRG1 
expression in SW480 to a level similar to that in SW620 (Figure 3.2a and 3.2b). Neither 
control siRNA (Figure 3.2a) nor NDRG1 siRNA (data not shown) affected the already 
minimal level of NDRG1 in SW620.  
The cellular properties of this pseudo-SW620 generated after knockdown of NDRG1 
in SW480 were further investigated. Results showed that the percentage of cells in G1 
phase decreased significantly after NDRG1 knockdown in SW480, combined with 
increased cell numbers in S and G2 phases (Figure 3.2c). After NDRG1 knockdown in 
SW480, the cells closely resembled the patern observed in SW620. Gene expression 
pattern of cell cycle regulators, including cyclin D1 and c-Myc, was also changed by the 
NDRG1 knockdown (Figure 3.2a).  
WST-1 assay showed that knocking down NDRG1 in SW480 also significantly 
reduced the proliferation of SW480 to the level of SW620 (Figure 3.2d). On the other 
hand, the apoptosis rate was not different between the two cell lines (~3%) and NDRG1 
knockdown in SW480 did not affect apoptosis (data not shown).  
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Cell adhesiveness was analyzed using adhesion assay. Using either fibronectin-coated 
or non-coated plates, the results showed that NDRG1 siRNA significantly reduced the 
absorbance reading which indicates reduced ability for SW480 cells to adhere to the plate 
(Figure 3.2e).  
Promoter DNA methylation was not involved in NDRG1 silencing in SW620 
There is a putative CpG island at the promoter region of the human NDRG1 gene (-
770/-250). Therefore, we tested the potential effects of DNA methylation on NDRG1 
expression. When DNA methylation was inhibited using 5-aza-cytidine, NDRG1 
expression in SW620 was significantly increased (Figure 3.3a). However, bisulfite 
sequencing of the CpG island revealed that there is minimal CpG methylation in both cell 
lines (Figure 3.3b), indicating indirect involvement of DNA methylation in NDRG1 
silencing.  
Chromatin modifications were associated with the regulation of NDRG1 expression 
in SW480 and SW620 
ChIP assay was performed to analyze the chromatin structure at the promoter 
(+19/+94), coding (+1489/+1968), and upstream control regions (-2494/-2427) of the 
NDRG1 gene (Figure 3.4a). Significantly higher binding of Pol II at the NDRG1 
promoter region in SW480 compared to SW620 demonstrated that the transcription of 
NDRG1 is highly active in SW480 compared to SW620 (Figure 3.4b).  Overall, 
compared to SW620, H4Ac was higher in SW480 and H3S10p was lower in all three 
tested regions of the NDRG1 gene.  On the other hand, H3Ac was not detected at any of 
the regions tested.  Meanwhile, H3K4me2 was much higher at the coding region but 
lower at the promoter region in SW480 compared to SW620 (Figure 3.4b).  To test the 
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potential interactions of histone modifications with DNA methylation, primers targeting 
the promoter CpG island of the NDRG1 gene were also used for the quantitative PCR in 
the ChIP analysis (from -584 to -517 within the CpG island -770/-250).  Results showed 
that the histone modification pattern in this region resembles what was observed for the 
promoter region (supplemental data).  The only difference is that at this upstream region 
away from the basal promoter region, Pol II activity is minimal so the PCR did not 
identify any Pol II binding at this region.   
Histone deacetylase (HDAC) inhibitor increased the NDRG1 mRNA expression in 
SW620 
 To comfirm the impact of histone acetylation on NDRG1 gene expression, we treated 
the SW620 cells with different concentrations of TSA, an HDAC inhibitor.  The NDRG1 
mRNA was increased 3 times by 50 nmol/L TSA and 20 times by 100 nmol/L TSA 
treatments, indicating that histone deacetylation might be involved in the silencing of 
NDRG1 in SW620 (Figure 3.5). 
Discussion 
The present study reported the following novel findings: 1) NDRG1 expression is 
silenced in the highly metastatic colon cancer cell line SW620; 2) Knockdown of 
NDRG1 in primary colon tumor-derived cell line SW480 made the phenotypes of  
SW480 shift toward that of SW620 in terms of gene expression, cell cycle progression, 
cell proliferation, and cell adhesion; 3) NDRG1 promoter methylation was not associated 
with the transcriptional silencing of NDRG1 but inhibition of general DNA methylation 
partially restored NDRG1 expression; 4) Several histone markers at the NDRG1 gene 
were closely related to the transcriptional repression in the highly metastatic cells.  
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The involvement of NDRG1 in cancer metastasis has been validated by many 
research groups in various cancer types [1, 3, 4, 6, 72]. In colon cancer, it has been 
reported that lower NDRG1 expression is associated with shorter 5-year survival rate [6]. 
And in vitro cellular study showed that knockdown of NDRG1 interfered with regulation 
of microtubule and resulted in abnormal cell division [63]. The present study showed 
higher S phase and G2 phase accumulation in the highly metastatic SW620, in contrast to 
the SW480 derived from primary tumor. More importantly, NDRG1 siRNA caused 
reduction of NDRG1 in SW480 and led to the shift of the number of cells in S phase and 
G2 phase. Accompanying this was the lower proliferation in SW620 and the NDRG1-
siRNA-treated SW480. Interestingly, it was reported recently that a global survey of 
colon cancers revealed that metastatic colon cancers have reduced proliferation compared 
to primary tumors [73]. The study showed that cell cycle gene expression along with 
Ki67 staining was decreased in metastatic tumors compared to primary tumors.  Our 
siRNA results warrant future studies on the involvement of NDRG1 in colon metastasis 
process at cell cycle control level.  
Our results support the involvement of DNA methylation in NDRG1 silencing.  It has 
been reported that in pancreatic cells, demethylation of genomic DNA in general also 
resulted in increased NDRG1 expression [74].  However, in the same report, bisulfite 
sequencing of the +38 to -388 region of NDRG1 CpG island did not show any DNA 
methylation in any of the pancreatic cells tested.  The putative CpG island we covered in 
our study, from -366 to -656, which is more upstream than what has been tested, did not 
show any DNA methylation either.  It is possible that DNA methylation of other regions 
of the NDRG1 gene is critical in regulating NDRG1 gene expression.  Future studies are 
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needed to test whether the NDRG1 gene silencing indirectly involves DNA methylation 
in colon cancer as has been observed in pancreatic cancer.  
Chromatin structure plays a key role in transcriptional regulation.  Post-translational 
modifications of histone tails determine the accessibility of the chromatin, and thus 
tightly regulate the transcription of a given gene.  Results from the ChIP on Pol II binding 
at the promoter verified the transcriptional regulation of the NDRG1 gene expression 
during colon cancer metastasis.  Furthermore, we surveyed the upstream, promoter, and 
coding regions of the NDRG1 gene for key histone modifications that occurred during 
colon cancer metastasis.  Apparently the regulation of NDRG1 gene expression is more 
associated with histone H4 acetylation than H3 acetylation as there are stronger signals 
detected in all regions for H4 acetylation.  Furthermore, the significantly higher H4 
acetylation in SW480 apparently contributed to the active transcription of the gene, 
supporting the common roles of the combined H4 acetylation at multiple lysine residues 
(normally lysine 5, 8, 12, and 16) in transcriptional regulation [75].  More importantly, 
the HDAC inhibitor TSA was able to de-repress the silenced NDRG1 in SW620 by 
increasing histone acetylation, confirming the role of histone acetylation in maintaining 
NDRG1 gene expression in SW480.  On the other hand, our result also proved that de-
acetylation of histone lysine residues contributes to the silencing of NDRG1 in SW620.  
In the present study, a decreased level of Me2H3K4 in the coding region of NDRG1 
in SW620 was correlated with down-regulation of NDRG1 expression in SW620, 
indicating that methylation of H3 lysine 4 was involved in transcriptional regulation of 
NDRG1.  It has been reported that a high level of Me2H3K4 is present at both 
transcription start sites and the transcribed regions [76].  At the same time, there is a 
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possibility of depletion of any histone at -200 to +50 region due to nucleosomal 
repositioning for some of the actively transcribed genes, leaving the signal from ChIP 
relatively low at this region [76].  Therefore, Me2H3K4 at the transcribing region serves 
as a better indicator of active transcription. The conundrum of histone H3 serine 10 
phosphorylation has been the focus of some research [77, 78].  Basically this particular 
histone modification occurs both at highly condensed mitotic chromosomes as well as 
transcriptionally active interphases. It is proposed that histone H3S10p provides a 
fundamental change in chromatin structure so that other histone modifications, either 
active or repressive, can interact and further regulate transcription.  The present study 
showed the correlation between increased histone H3S10p and the silencing of the 
NDRG1 gene in SW620.  Further studies on the kinase(s) that phosphorylates this site are 
needed to link the histone phosphorylation to transcriptional regulation of NDRG1.  
Taken together, results from this study suggested that histone modifications could 
provide mechanisms of NDRG1 repression during colon cancer metastasis.  
Materials and Methods 
Cell culture  
The human colon cancer cell lines SW480 and SW620 were purchased from ATCC 
(Manassas, VA). Minimum essential medium (MEM) was purchased from the Cell 
Media Facility at the University of Illinois. Unless otherwise mentioned, all general 
chemicals and laboratory supplies were obtained from Fisher Scientific 
(www.fishersci.com). Cell culture ware was purchased from Sarstedt (Newton, NC). 
Both cell lines were cultured in MEM, supplemented with 10% fetal bovine serum (FBS) 
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and 1% antibiotic-antimycotic solution (ABAM) at 37 °C in a humid incubator with 5% 
CO2. All experiments were performed using cells with 2-6 passages. Cell line verification 
was routinely performed in the laboratory according to the guidelines by ATCC 
(Technical Bulletin No. 8, www.atcc.org).  
Quantitative real-time PCR 
Cells were harvested in TriReagent (Sigma-Algrich, St Louis, MO). Total RNA was 
isolated following the manufacturer’s instructions. RNA concentration was detected by 
SmartSpec Plus Spectrophotometer (BioRad, Hercules, CA). cDNA was synthesized 
from total RNA using High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Foster City, CA). cDNA was then analyzed by two-step real-time PCR using 
7300 real-time PCR system (Applied Biosystems) and detected with SYBR Green. In 
each reaction, 25 ng of synthesized cDNA were used in a 20 µL volume containing 10 
µL Perfecta SYBR Green fast master mix (2x, Quanta BioSciences, www.vwr.com ) and 
0.25 µmol/L of each primer. Real-time PCR was performed using the following program:  
95C for 10 min, 35 cycles of 95C for 15 s followed by 60C for 1 min. A serially 
diluted cDNA sample was used in the same PCR reaction to generate a standard curve, 
based on which the quantity of the unknown samples was calculated. Standard curves 
with slope -3.10±0.20 and R
20.99 were accepted.  L7a was used as an internal control to 
normalize raw data. PCR primers were synthesized by Integrated DNA Technologies 
(www.idtdna.com). The sequences are as follows: NDRG1, sense 5′-
GCTGGCTGAAATGCTTCCTGG-3′ and antisense 5′-TGCTCCTGTTCCCATGCCAA-
3′; L7a, sense 5′-TTTGG CATTGGACAGGACATCC -3′ and antisense 5′-
AGCGGGGCCATTTCACAAAG -3′; cyclin D1, sense 5′- 
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CGCCCTCGGTGTCCTACTTCAA -3′ and antisense 5′- GTG GCG ACG ATC TTC 
CGC AT -3′; c-Myc, sense 5′- GCTCCTGGCAAAAGGTCAGAGTCT -3′ and antisense 
5′- ACCAGTGGGCTGTGAGGAGGTT -3′. 
Western blotting analysis 
Cells were lysed by 500 µL lysis buffer (0.125 mol/L Tris–HCl,pH 6.8, 1% SDS, 
0.04% bromophenol blue, and 20% glycerol, v/v ) with a proteinase inhibitor (Roche) and 
a phosphotase inhibitor cocktail (Sigma-Aldrich). Total protein was size-fractionated on a 
12% Tris–HCl polyacrylamide gel and transferred at 14 V onto a PVDF membrane (Bio-
Rad) at 4 ºC for 1 h. PVDF membranes were incubated with blocking solution containing 
10% (w/v) nonfat dry milk (NFDM), 20 mmol/L Tris–HCl with pH 7.6, 137 mmol/L 
NaCl, and 0.1% (v/v) Tween-20 for 1.5 h at room temperature. Antibody against NDRG1 
(N8539, Sigma-Aldrich) was diluted 1:1000 in 10% NFDM blocking solution and 
incubated at room temperature for 3 h. Subsequently, the membranes were washed with 
blocking solution containing 5% NFDM for 5 x 5 min. Goat anti-rabbit HRP-conjugated 
secondary antibody was diluted 1:10000 in blocking solution containing 5% (w/v) 
NFDM and incubated for 1 h at room temperature. After washing 5x 5 min in blocking 
solution containing 1% (w/v) NFDM, the membranes were exposed to the enhanced 
chemiluminescence reagent SuperSignal West Dura (Pierce). Signals were detected by 
ChemiDoc XRS imaging system (Bio-Rad).  
Small interfering RNA (siRNA) transfection 
SW480 and SW620 cells were plated at 0.4 ×10
6
 per well in 6-well plate or 2000 per 
well in 96-well plates and incubated overnight at 37 °C with 5% CO2. At the time of 
transfection, 200 nmol/L of siRNA against human scramble sequence (N.C.si, QIAGEN, 
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Valencia, CA) or NDRG1 (NDRG1 si, Integrated DNA Technologies) was prepared in 
200 µL serum-free media (SFM). The siRNA solution was incubated with 5 µL 
DharmaFect#2 (in 200 µL SFM, Dharmacon, www.fishersci.com ) at room temperature for 
20 min to form the transfection complex. Each well of the 6-well plates and the 96-well 
plates was replenished with 1.6 mL and 80 µL fresh MEM, respectively before the 
transfection complex was added (400 µL/ well for 6-well plates and 20 µL/ well for 96-
well plates). The transfected cells were incubated at 37 °C for 48 h for mRNA, cell cycle, 
apoptosis and proliferation analysis and 72 h for protein analysis. siRNA duplex for 
NDRG1 used is as follows:  5'- 
rCrCrUrArCrArUrCrCrUrArArCrUrCrGrArUrUrUrGrCrUCT- 3', and 5'-
rArGrArGrCrAr ArArUrCrGrArGrUrUrArGrGrArUrGrUrArGrGrCrG- 3' 
(HSC.RNAI.N00135242.11.8, Integrated DNA Technologies). 
Cell cycle analysis by flow cytometry 
At the end of siRNA transfection as described above, cells were trypsinized, 
centrifuged at 1000 rpm, and resuspened in 0.5 mL 1xPBS. To fix the cells, 0.5 mL 100% 
cold ethanol was added to each sample and incubated for a minimum of 20 min. After 
centrifugation at 1000 rpm for 5-7 min, ethanol was decanted and Propidium Iodide (PI)-
RNase solution of 0.5 mL (final concentrations: 50 µg/mL PI + 100 µg/mL RNase A in 
1x PBS) was added to the pellet and mixed well. Samples were incubated at room 
temperature in the dark for a minimum of 20 min before analysis by flow cytometry. 
Each sample was repeated three times. Cell cycle data was analyzed by software FCS 3.0.  
Cell proliferation analysis using WST-1 assay 
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At the end of siRNA transfection as described above, 10 μL of cell proliferation 
reagent WST-1 (Roche) was added to each well of the 96-well plates and incubated for 4 
h. At the same time, a serially diluted and known number of cells were mixed with the 
same amount of the WST-1 reagent and aliquoted to the unused wells of the same 96-
well plate to generate the standard curve for converting the absorbance reading to cell 
numbers. The 96-well plate was shaken thoroughly for 1 min on a shaker and the 
absorbance of the samples was read at 450 nm against reference wavelength 630 nm by a 
microplate reader (ELX800, BioTek, Winooski, VT).  
Apoptosis assay by flow cytometry 
After siRNA transfection as described above, cells were trypsinized, centrifuged at 
1000 rpm for 7 min, and washed once with 0.5 mL PBS. Cell pellets were resuspended in 
500 µL of Annexin-V binding buffer containing 5 µL of Annexin V-FITC and 5 µL of PI 
(50 µg/mL) and incubated at room temperature in the dark for 15 min. Apoptosis was 
analyzed in triplicate by flow cytometry within 1 h. Each sample was repeated three 
times. Data from flow cytometry was analyzed by software FCS 3.0. 
Adhesion assay 
Both fibronectin-coated and non-coated 96-well plates were used for the cell adhesion 
assay. For coating, plates were treated with 0.3 µg fibronectin at 37 C for 1 h.  Cells 
were blocked with blocking buffer (0.5% BSA in MEM) at 37 C for 1 h before plating.  
For each well, 0.02×10
6 
 cells were plated and incubated in cell culture incubator for 30 
min. Adherent cells were fixed with 4% paraformaldehyde and then stained with crystal 
violet (5 mg/mL in 2% ethanol) for 10 min and washed with water. Fifty µL of 2% SDS 
was added to air-dried wells and incubated at room temperature for 30 min. The plate was 
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read at 562 nm in a microplate reader ELx800 (BioTek, Winooski, VT). Level of 
absorbance at 562 nm represents numbers of adherent cells.  
5-Aza-cytidine and trichostatin A (TSA) treatments 
SW480 and SW620 cells were plated at 0.2 ×10
6
 per dish in a 60 mm culture dish in 
regular MEM containing 10% FBS and 1% ABAM. After overnight incubation, cells 
were treated with culture media containing 0, 4, or 8 µmol/L 5-Aza-cytidine 
(Azacitidine) or 50 or 100 nmol/L TSA for 2 d. Treatment media was refreshed after 24 
h. Total RNA was isolated after the treatment and mRNA expression was analyzed by 
real time RT-PCR as described above.   
Chromatin immunoprecipitation (ChIP)   
To determine the specific histone modifications and transcription factor binding 
within the NDRG1 gene, ChIP analysis was performed according to a modified protocol 
[79]. Cells were trypsinized and washed with PBS. Cross-linking was set in 1% 
formaldehyde for 10 min on a rotator at room temperature. The pellet was resuspended in 
nuclei swelling buffer (5 mmol/L Pipes pH 8.0, 85 mmol/L KCl, 0.5 % NP40) and lysed 
in SDS lysis buffer (50 mmol/L Tris-HCl pH 8.1, 10 mmol/L EDTA, 1% SDS) 
containing protease inhibitors. The chromatin was sonicated using a Sonic Dismembrator 
(model F100, Fisher Scientific) with power set at 5 on ice for 7 bursts of 40 s each. 
Sheared chromatin was diluted to 10 mL with ChIP dilution buffer, aliquoted, and 
incubated overnight with 2 µg of antibody/mL. The chromatin-antibody complex was 
precipitated with 60 µL of 50% pre-blocked protein G-agarose slurry (Millipore). Normal 
rabbit IgG was used as the negative control. Supernatant from the normal rabbit IgG was 
saved as the input. The protein G-agarose beads were washed sequentially with 1 mL of 
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the following solutions: low salt (20 mmol/L pH 8.0 Tris-HCl, 0.1% SDS, 2 mmol/L 
EDTA, 150 mmol/L NaCl, 1% triton X-100), high salt (20 mmol/L pH 8.0 Tris-HCl, 
0.1% SDS, 2 mmol/L EDTA, 500 mmol/L NaCl, 1% triton X-100), LiCl (10 mmol/L pH 
8.0 Tris-HCl, 0.25 mmol/L LiCl, 1% NP40, 1 mmol/L EDTA, 1% sodium deoxycholate) 
and TE (pH 8.0). Chromatin complexes were eluted with 2x 250 µL of the elution buffer 
(1% SDS and 50 mmol/L NaHCO3) at 37C for 15 min each and reversed-crosslinked 
with 0.2 mol/L NaCl at 65C for 5 h. Chromatin DNA was purified using QiaPrep 
miniprep kit (Qiagen) after proteinase K digestion. Immunoprecipitated DNA was 
detected by real time PCR using primers targeting different regions of the NDRG1 gene: 
promoter region (+19/+94), sense 5′- GCCTATAAAGTCGCCCTCCG -3′ and antisense 
5′- AACTGACGAGCTTCAGCACCA -3′; coding region (+1489/+1568), sense 5′- 
TCAGAAGTCAGCCAGTGGCCAG -3′ and antisense 5′- 
TAGGAGAAGGTCCCGTGCAGCT -3′; upstream control region (-2494/-2427), sense 
5′- AGGATAACAGGCACACAGGCTGC -3′ and antisense 5′- 
ATCTCTGGGAGCCATCCTGCTG -3′; CpG island region (-584/-517): sense 5′- 
GGTGGGCAAGATGGACGAGAT -3′ and antisense 5′- 
TTCTCAGCCTTCCGTGTCGC -3′. The antibodies used are as follows: Acetylated 
histone H3 (H3Ac, 06-599, Millipore), acetylated histone H4 (H4Ac, 06-866, Millipore), 
dimethyl-histone H3 lysine 4 (H3K4me2, 07-030, Millipore), trimethyl-histone H3 lysine 
27 (H3K27me3, 07-449, Millipore), normal rabbit IgG (IgG, sc-2027, Santa Cruz 
Biotechnologies, Santa Cruz, CA), RNA polymerase II (Pol II, sc-899, Santa Cruz), 
phosphorylated histone H3 serine 10 (H3S10p, sc-8656R, Santa Cruz). 
Bisulfite sequencing 
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Genomic DNA was isolated from SW480 and SW620 with DNeasy Tissue Kit 
(Qiagen). Bisulfite conversion was performed with 1.4 µg of total genomic DNA using 
EZ Methylation-Gold kit (Zymo Research, Orange, CA) according to the manufacturer’s 
instructions. After purification, 200 ng of converted DNA was used as the template for 
each PCR reaction. Promoter CpG island for NDRG1 was predicted as being located at -
770 to -250 (http://www.ebi.ac.uk/emboss/cpgplot/) and primers were designed to 
amplify -656 to -366 region: sense 5’- TTTAGTGGGTAAGGTTTAGTGAGTGT-3’, 
and antisense 5’- CCTCAAAATTTCTTCTAAAAATCTC-3’. The amplicons were 
cloned using TOPO-PCR cloning kit (Invitrogen) and sequenced at the Biotechnology 
Center at the University of Illinois at Urbana-Champaign (Urbana, IL). 
Statistical analysis 
Unpaired two-tailed Student’s t test was performed for mRNA expression, cell 
proliferation, cell cycle, and apoptosis analyses. Two-way ANOVA using LSMeans was 
performed for ChIP results (SAS Institute Inc., Cary, NC). Data are presented as mean ± 



































































































Figure 3.1 NDRG1 expression was repressed in metastatic 
colon cancer cell line SW620. a) NDRG1 mRNA expression. 
mRNA expression was analyzed by real-time RT-PCR. Data 
were normalized to internal control L7a. Three independent 
cell samples were analyzed and presented as the mean  SEM.  
* indicates statistical significance compared to SW480 
(p<0.05). b) Western blot analysis of NDRG1 protein.  The 
NDRG1 protein was detected by western blot using an 
antibody against c-terminus of human NDRG1. β-actin was 
used as the loading control (data not shown).  
 






                                                                                      
































Figure 3.2 Effects of NDRG1 knockdown by siRNA in SW480. SW480 was transfected with 
scrambled siRNA (ctrl si) and NDRG1 siRNA and SW620 with ctrl si for 48 h (for mRNA and cell 
cycle analysis) or 72 h (for protein analysis). The following analyses were performed at the end of the 
transfection: a) mRNA expression of NDRG1, cyclin D1, and c-Myc by real-time RT-PCR.  Data 
were normalized to internal control L7a.  b) Western blot analysis of NDRG1 protein. β-actin was 
used as the loading control. c) Cell cycle analysis by flow cytometry.  Each sample was repeated three 
times. Cell cycle data was analyzed by software FCS 3.0. Each bar represents the percentage of cells 
in the specified cell cycle stage. d) WST-1 proliferation assay. WST-1 signals from each well were 
read by the absorbance at 450 nm against reference wavelength 630 nm. Absorbance was converted to 
actual cell numbers (y axis label) using a serial numbers of cells aliquoted to the same 96-well plate as 
the standard curve. e) Cell adhesion assay. Fibronectin-coated and non-coated plates were used for the 
assay. The adherent cells were fixed and stained with crystal violet. The numbers of adherent cells 
were estimated by absorbance reading at 562 nm.  For all experiments, three independent cell samples 
were analyzed and presented as the mean  SEM.  Asterisks (*) indicate statistical significance 
compared to SW480 with ctrl si (p<0.05).  
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Figure 3.3 a) NDRG1 mRNA in SW620 after 5-aza-Cytidine (Azacitidine) 
treatment. NDRG1 mRNA level was tested in SW480 and SW620 treated 
with Azacitidine (0, 4 and 8 µmol/L) for 48 h. mRNA was analyzed using 
real-time RT-PCR. Three independent cell samples were analyzed and 
presented as the mean  SEM.  Asterisks (*) indicate statistical significance 
compared to SW480 (p<0.05). b) Bisulfite sequencing of NDRG1 in SW480 
and SW620. Horizontal bar represents the CpG island in the promoter 
region. The vertical bars indicate individual CpG sites. Black arrows 
indicate the positions of the primers used for PCR amplification of the 
region for sequencing (-656 to -366). The C in a CpG is denoted as 
unmethylated when sequencing result showed “T” and as methylated when 
sequencing result showed “C”. Each open circle represents an unmethylated 
CpG while a filled circle represents a methylated CpG. Each row of circles 
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Figure 3.4 ChIP analysis of chromatin modifications in SW480 and 
SW620. a) A schematic drawing of the regions analyzed. Black arrow 
heads represent three regions tested by real-time PCR (positions are 
numbered).  b) Relative protein abundance by ChIP. 
Immunoprecipitated DNA was detected by real time PCR. Antibodies 
used for immunoprecipitation of chromatins are labeled on x axis. 
Three independent experiments were analyzed and presented as the 
mean  SEM.  Asterisks (*) indicate statistical significance compared 
to SW480 with the same antibody treatment (p<0.05). 
 









































Figure 3.5 NDRG1 mRNA in SW620 after TSA treatment. NDRG1 
mRNA level was tested in SW480 and SW620 treated with TSA (0, 50, 
and 100 nmol/L) for 48 h. mRNA was analyzed using real-time RT-
PCR as described. Three independent cell samples were analyzed and 
presented as the mean  SEM.  Asterisks (*) indicate statistical 
significance compared to SW480 (p<0.05).  
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CHAPTER 4 
Silencing of Wnt5a during colon cancer metastasis involves  





Colorectal cancer (CRC) is the third most common cancer in the United States. 
Approximately 90% of colon cancer deaths arise from the metastasis of primary tumors. 
Aberrant expression of WN5a, one of the WNT signaling factors, has been reported 
during colon cancer development and progression. We found that both mRNA and 
protein expression of Wnt5a were decreased in the highly metastatic human colon cancer 
cell line SW620 compared to the non-metastatic human colon cancer cell SW480.  This 
study tested the hypothesis that the silencing of Wnt5a in metastatic human colon cancer 
cells is related to altered epigenetic modifications.  Wnt5a expression was not responsive 
to DNA methyltransferase inhibitor 5-aza-cytidine treatment.  However, histone 
deacetylase (HDAC) inhibitors trichostatin A (TSA) and sodium butyrate (NaBt) both 
significantly increased the mRNA expression of Wnt5a in SW620.  Importantly, the 
lower transcription of Wnt5a in SW620 than SW480 corresponded to multiple histone 
modifications, including lower levels of acetylated histone H3 and H4 (H3Ac and H4Ac), 
dimethyl H3 lysine 4 (H3K4me2), and higher levels of trimethyl H3 lysine 27 
(H3K27me3) in the promoter region.  The increase of H3Ac, H4Ac, and H3K4me2 after 
NaBt treatment in SW620 confirmed the involvement of histone modifications in the 
transcriptional regulation of Wnt5a.  Additionally, NaBt treatment increased β-catenin 
                                                          
2This chapter is based on our published paper “Li Q, Chen H(2012). Silencing of Wnt5a during colon 
cancer metastasis involves histone modifications of the gene. Epigenetics. 2012 Jun 1;7(6):551-8.”  
 
- 35 - 
 
signaling and diminished the difference in cell adhesion ability between non-metastatic 
SW480 and metastatic SW620, suggesting that the HDAC inhibitor plays critical roles in 
Wnt signaling pathway and cell physiology that relate to metastasis.  In conclusion, our 
study suggests the importance of Wnt5a in colon cancer metastasis and also indicates that 
the silencing of Wnt5a in the highly invasive human colon cancer cell line might result 
from transcriptional regulation of the gene by histone modifications. 
Introduction 
       Colorectal cancer (CRC) is the third most common and the third death-leading 
cancer in the United States [80]. It accounts for 9–10% of deaths from cancer [80]. 
Despite the recent and continuous improvements in diagnosis and treatments, more than 
50% of CRC metastasize to liver, lung and lymph nodes [2]. The five year survival rate 
remains below 50% for patients with metastatic CRC. Thus, there is an urgent need to 
elucidate the mechanism of CRC metastasis. 
       Wnt5a is one of the glycoproteins in the Wnt family of signaling molecules. It has 
been shown to stimulate the intracellular Ca2+ release and activation of PKC (i.e., non-
canonical Wnt pathway) [81, 82]. In addition, Wnt5a is involved in the canonical WNT 
signaling pathway (i.e., β-catenin-mediated pathway) by either activating or antagonizing 
it [82-85]. These diverse characteristics may be attributed to the tumor-suppressing or 
tumor-stimulating effects of Wnt5a, depending on cancer types and stages [12-14, 86]. 
For example, upregulation of Wnt5a is associated with breast cancer [87], prostate cancer 
[13] and melanoma [12], suggesting its oncogene role in these cancers. On the other 
hand, it shows tumor-suppressing effects in colorectal cancer [14], thyroid cancer [86] 
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and acute lymphoblastic leukemia [88]. Specifically in colon cancer, Dejmek et al. 
reported that Wnt5a protein expression was reduced in Dukes B colon carcinomas 
compared with normal colon tissue [10]. They also detected that Wnt5a expression was 
negatively correlated with 5-year survival of patients, suggesting the loss of Wnt5a as a 
potential prognostic marker for colon cancer progression [14]. The Wnt5a protein has 
been shown to regulate cell adhesion, motility and polarity [10, 89]. Knockdown of 
Wnt5a impaired cell adhesion and spreading, indicating its important role in cell adhesion 
[90]. β-catenin/E-cadherin-mediated cell-cell adhesion was reduced by loss of Wnt5a in 
breast carcinomas, suggesting Wnt5a is a good prognostic factor for longer disease-free 
survival in human breast cancer [87]. In colon cancer, Wnt5a inhibited cell proliferation 
and impaired cell migration, a function that is necessary for tumor invasion and 
metastasis [10, 86]. The function of Wnt5a in colon cancer suppression suggests its 
potential for inhibiting CRC metastasis. 
       It has been shown that epigenetic regulation, mainly DNA methylation and histone 
modifications, play important roles in the expression of Wnt5a. Ying et al. [14] observed 
silencing of Wnt5a in most CRC cell lines due to promoter methylation. Jensen et al. [15] 
reported that arsenic exposure in human bladder cancer cells induced histone 
modifications in correspondence with the transcriptional activation of Wnt5a. However, 
the relationship between Wnt5a expression and epigenetic modifications in CRC 
metastasis remains undefined. 
        To understand the epigenetic regulation of Wnt5a in the progression of colon cancer 
metastasis, we used two human colon cancer cell lines, SW480 and SW620, which have 
been established from the same colon cancer patient. SW480 was derived from a colon 
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carcinoma in the 50-y-old male patient, while SW620 was derived from the lymph node 
metastases in the same patient one year later [70]. Although these two cell lines are 
isogenic, they differ remarkably in many cell properties, such as cell morphology, 
tumorigenicity, adhesion, migration capacity and metastatic potential [8, 91, 92]. The 
unique properties of SW480 and SW620 make them a good model for studying 
epigenetic modifications in the late stages of colon cancer progression. 
          In the current study, we aimed to test the hypothesis that CRC metastasis is 
associated with aberrant expression of Wnt5a, which is regulated by epigenetic 
mechanisms. Repression of Wnt5a in SW620 corresponded with histone modifications 
and was partially reversed by HDAC inhibitors. HDAC inhibitor also modified β-catenin 
and enhanced the adhesion ability of SW620. Taken together, our findings indicate that 
histone modifications play important roles in CRC metastasis by regulating Wnt5a 
signaling. 
Results 
Wnt5a was silenced in the highly metastatic cell line SW620 
To compare the mRNA expression of Wnt5a in human colon cancers with different 
invasiveness, real-time PCR analysis was performed in colon cancer cell line SW480 that 
was established from the primary tumor site and the highly metastatic cell line SW620 
that was established from a lymph node metastasis from the same patient a year later.  
Wnt5a mRNA in SW480 was approximately 1000 times higher than that in SW620 
(p<0.05, Figure 4.1a).  
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        We also tested the Wnt5a protein expression by immunofluorescent staining (Figure 
4.1b, anti-Wnt5a). Quantitative analysis of immunofluorescent staining indicated that 
Wnt5a protein was significantly less expressed in SW620 compared to SW480 (p<0.05, 
Figure 4.1c), which was consistent with the mRNA expression analysis by real-time 
PCR. 
Histone deacetylase (HDAC) inhibitors, but not DNA methylation inhibitor, 
increased Wnt5a expression in SW620 
        There are two putative CpG islands in the promoter region of human Wnt5a gene 
from (-1000) to exon 1 (predicted by http://www.urogene.org/methprimer), indicating the 
possible role of DNA methylation in the regulation of Wnt5a gene expression in human.  
To examine the involvement of DNA methylation in the silencing of Wnt5a in SW620, 
we treated SW620 with 4 and 8 µmol/L of the DNA methylation inhibitor 5-aza-cytidine. 
The mRNA expression of Wnt5a did not change after 5-aza-cytidine treatment (Figure 
4.2a), which suggested that the decreased expression of Wnt5a in SW620 was not 
directly caused by DNA methylation. 
To test whether histone acetylation contributes to altered expression of Wnt5a during 
colon cancer metastasis, we exposed SW620 to HDAC inhibitors TSA (50 or 
100 nmol/L) and NaBt (2.5 or 5 mmol/L).  Both TSA and NaBt increased the expression 
of Wnt5a mRNA in a dose-dependent manner.  mRNA expression of Wnt5a was up-
regulated ~8 times by 100 nmol/L of TSA and ~14 times by 5 mmol/L of NaBt (p<0.05, 
Figure 4.2b).  This observation indicates that HDAC was involved in the regulation of 
Wnt5a expression in a cell line that models the development of colon cancer metastasis.  
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Histone modifications were associated with the regulation of Wnt5a expression in 
SW480 and SW620 
To further test our hypothesis that histone modifications are involved in regulating 
Wnt5a expression in colon cancer cells, we used ChIP to investigate the chromatin 
structure at the promoter region (Figure 4.3a, upper panel) and coding region (Figure 
4.3a, lower panel) of the gene.  When comparing SW480 and SW620, we observed much 
lower levels of H3Ac, H4Ac, and H3K4me2 in SW620; whereas H3K27me3 in SW620 
was higher than that in SW480.  Moreover, the promoter region and coding region 
showed similar patterns in terms of chromatin structure among the two cell lines even 
though they are 6 kb apart (Figure 4.3). 
      ChIP was also performed in SW620 following NaBt (5 mmol/L) treatment.  After the 
48 h treatment, H3Ac was significantly increased at the promoter region (p<0.05, Figure 
4.3b, upper panel), but not at the coding region (Figure 4.3b, lower panel).  NaBt 
treatment also significantly induced dimethylation at histone H3 lysine 4 in both the 
promoter and the coding regions of Wnt5a in SW620 (p<0.05, Figure 4.3b, H3K4me2).  
Moreover, under NaBt treatment, the level of H3K4me2 was ~4 times higher at the 
promoter region than that at the coding region (p<0.05, Figure 4.3b).  
HDAC inhibitor up-regulated the WNT signaling pathway in SW620 
      To examine the impact of HDAC inhibitor on the WNT signaling pathway, we 
examined the NaBt-treated SW620 cells for the expression of β-catenin, the key 
component of WNT signaling, by immunofluorescent staining (Figure 4.4a).  
Quantitative analysis showed that β-catenin protein content was much lower in SW620 
than in SW480 (p<0.05, Figure 4.4b).  NaBt treatment restored/increased β-catenin levels 
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in SW620to levels even higher than that in SW480 (p<0.05, Figure 4.4b).  This 
observation suggests that the expression of Wnt5a in these human colon cancer cell lines 
is positively associated with the activation of β-catenin.  
HDAC inhibitor enhanced adhesion ability of SW620 to the level similar to that in 
SW480 
      An in vitro cell adhesion assay was performed to investigate the impact of Wnt5a on 
cell adhesion, which is related to cell interactions and cancer metastasis (Figure 4.4c).  
The adhesion ability of SW620 was less than SW480 (p<0.05).  Importantly, NaBt 
treatment elevated the cell adhesion of SW620 and diminished the difference between the 
two cell lines.   
Discussion 
      In this study, mechanistic analysis was conducted to determine the relationship 
between colon cancer metastasis and silencing of Wnt5a.  Highly metastatic colon cancer 
cell line SW620 showed much lower expression of Wnt5a as well as lower activity of the 
WNT signaling pathway than the primary colon cancer cell line SW480.  More 
importantly, the restoration of Wnt5a expression by HDAC inhibitors and the 
corresponding changes in chromatin modifications in SW620 indicates that the silencing 
of the Wnt5a gene in SW620 was mainly due to histone modifications that occurred at its 
gene regions.   
It has become increasingly evident that epigenetic changes contribute to cancer 
progression and metastasis [34, 93, 94].  HDAC was responsible for the suppression of E-
cadherin in metastatic pancreatic cancer and thus induced the epithelial to mesenchymal 
transition [95].  Epigenetic downregulation of secreted frizzled-related protein 5 
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(SFRP5), an antagonist of the WNT signaling pathway, lead to cancer progression [96, 
97].  Moreover, our group previously reported that the metastasis suppressor NDRG1 was 
transcriptionally down-regulated by epigenetic alterations in CRC metastasis [8].  The 
present study showed that the epigenetic silencing of Wnt5a, a WNT signaling molecule, 
was involved in CRC metastasis.  
Histone modifications, such as acetylation, methylation and phosphorylation, 
influence gene expression by altering chromatin environments [76].  The present study 
revealed that multiple histone modifications were associated with the aberrant expression 
of Wnt5a in metastatic colon cancer cell line SW620.  The silencing of Wnt5a in SW620 
was positively correlated with the low levels of active histone modifications, including 
the acetylation of histone H3 and H4, and the methylation of histone H3 lysine 4 at its 
promoter.  We also tested the levels of the repressive histone marker H3K27me3, whose 
enrichment correlates with gene repression not only in normal development [98] but also 
in cancers [99, 100].  Moreover, the silencing of tumor-suppressor genes in cancer 
regulated by H3K27me3 has been shown to be potentially independent of promoter DNA 
methylation [99].  In the present study, we observed much higher levels of H3K27me3 in 
SW620 than in SW480, which was consistent with the lower expression of Wnt5a in 
SW620.  H3K9me3 was implicated in gene silencing [101].  However, H3K9me3 in both 
SW480 and SW620 was nearly undetectable, suggesting that the methylation of H3K9 
did not influence Wnt5a expression in this case.  Apart from histone acetylation and 
methylation, histone phosphorylation may also affect the expression of Wnt5a.  
Phosphorylated H3S10 plays a critical role in the dynamic condensation/ decondensation 
during the cell cycle [102].  The changes in chromatin structure induced by the 
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phosphorylation of histone H3S10 cause other histone modifications, either active or 
repressive, that interact and further regulate transcription [78].  The present study 
indicates that increased phosphorylation of histone H3S10 may be associated with the 
silencing of the Wnt5a gene in SW620. 
The status of histone acetylation in SW480 and SW620 were consistent with our 
finding that Wnt5a mRNA was significantly increased by the treatment with HDAC 
inhibitors TSA and NaBt, which belong to two types of HDAC inhibitors [103].  Both 
TSA and NaBt induced Wnt5a expression in a concentration-dependent manner.  To 
specifically test the impact of HDAC inhibitors on the histone landscape, ChIP was 
performed in SW620 following NaBt treatment.  Interestingly, both acetylated histone H3 
and methylated H3 lysine 4 were significantly increased in the promoter region by NaBt 
induction.  A similar observation was reported by Mossman et al. [104], leading to the 
conclusion that transcriptional reactivation of epigenetically-silenced genes in colon 
cancer cells requires increased H3 acetylation and H3 methylation. 
Our study also indicates that the HDAC inhibitor altered the WNT signaling pathway 
and caused metastasis-related physiological changes.  As the key component of canonical 
WNT signaling, β-catenin acts as the marker of the activation of the pathway.  Although 
Wnt5a activates β-catenin-independent signaling and was mostly considered as the 
antagonist of the β-catenin-dependent WNT pathway [105], several studies showed that 
overexpression of Wnt5a and its receptors activated the β-catenin pathway [83, 85].  Our 
finding suggested that the up-regulation of Wnt5a by NaBt exposure induced the 
activation of β-catenin signaling.  Furthermore, NaBt exposure increased the cell 
adhesion ability of SW620 to a level similar to that of SW480, indicating the impact of 
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HDAC inhibition on the physiology of metastatic colon cancer cells.  The change in cell 
adhesion ability may be attributed to the increased Wnt5a expression by HDAC inhibitor, 
because it was shown that knockdown of Wnt5a impaired cell adhesion and spreading 
[90].  Further research needs to be conducted to investigate the role that epigenetic 
mechanisms of histone modifications may have in Wnt5a gene expression, and these 
future findings may lead to epigenetic therapies for colon cancer metastasis.   
Several studies have shown that Wnt5a expression was regulated by DNA 
methylation [57, 88, 106]. Our current finding that Wnt5a was silenced in SW620 but not 
in SW480 was consistent with the report by Ying et al., showing that Wnt5a was silenced 
in four out of six human colon cancer cell lines [14].  They indicated the possible 
correlation of down-regulation of Wnt5a in SW620 to the high methylation status at its 
promoter, as tested by methylation-specific PCR (MSP).  In the current study, we did not 
detect the induction of Wnt5a expression after 5-aza-cytidine treatment in SW620, 
indicating the lack of response to DNA demethylation in SW620.  Therefore, at least in 
SW620 cells, the hypermethylation of the Wnt5a promoter may be a consequence of a 
generally high DNA methylation environment in SW620 and it is not directly linked to 
the transcriptional regulation of Wnt5a.  Considering the complexity of epigenetic 
modifications in colon cancer progression, future research is critically needed to study the 
interactions of different epigenomic components, mainly DNA methylation and 
histone/chromatin modifications. 
Taken together, this study provides insights into the epigenetic modifications of 
Wnt5a, a critical mediator of the WNT signaling pathway, which was decreased during 
CRC metastasis.  Our study also provides more evidence in terms of the general effects of 
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HDAC inhibitors on the commonly aberrant WNT signaling pathway in advanced CRC 
stages.  Our findings advance the understanding of molecular mechanisms of colon 
cancer metastasis, especially at the level of epigenetic remodeling.   
Materials and Methods 
Cell culture  
The human colon cancer cell lines SW480 and SW620 were purchased from ATCC 
(Manassas, VA).  SW480 and SW620 are isogenic cell lines established from the colon 
cancer of the same patient [70].  SW480 was the primary colon cancer derived from the 
patient and SW620 was derived from the lymph node metastasis from the same person 
one year later.  Minimum essential medium (MEM) were purchased from the Cell Media 
Facility at the University of Illinois.  Unless otherwise mentioned, all general chemicals 
were obtained from Fisher Scientific (www.fishersci.com).  Cell culture ware was 
purchased from Sarstedt (Newton, NC). Both cell lines were cultured in MEM, 
supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic solution 
(ABAM) at 37°C in a humid incubator with 5% CO2. All experiments were performed 
using cells with 2-6 passages. Cell line verification was routinely performed in the 
laboratory according to the guidelines by ATCC (Technical Bulletin No. 8, 
www.atcc.org).  
5-aza-cytidine, TSA and NaBt treatment 
SW480 and SW620 cells were plated at 0.3 ×10
6
 per 60 mm culture dish in regular 
growth media. After overnight incubation, cells were treated with culture media 
containing 0, 4, or 8 µmol/L 5-aza-cytidine (Azacitidine, Sigma-Aldrich, St Louis, MO), 
- 45 - 
 
50 or 100 nmol/L TSA (Sigma), or 2.5 or 5 mmol/L NaBt for 2 d. Treatment media were 
refreshed after 1 d. Total RNAs were isolated after each treatment and mRNA expression 
was analyzed by real time PCR as described below.  
Quantitative real-time PCR 
Cells were harvested in TriReagent (Sigma-Aldrich, St Louis, MO). Total RNAs were 
isolated following the manufacturer’s instructions. cDNA was synthesized from total 
RNA using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster 
City, CA).  cDNA was then analyzed by two-step real-time PCR using the 7300 real-time 
PCR system (Applied Biosystems) and detected with SYBR Green. In each reaction, 25 
ng of synthesized cDNA were used in a 20 µL volume containing 10 µL Perfecta SYBR 
Green fast master mix (2×, Quanta BioSciences, www.vwr.com ) and 0.25 µmol/L of 
each primer. Real-time PCR was performed using the following program:  95C for 10 
min, 40 cycles of 95C for 15 s followed by 60C for 1 min. A serial dilution of a cDNA 
sample was used in the same PCR reaction to generate a standard curve, based on which 
the quantity of the unknown samples was calculated. Standard curves with slope of -
3.3±0.2 and R
20.98 were accepted.  L7a was used as an internal control to normalize 
obtained raw data. PCR primers were synthesized by Integrated DNA Technologies 
(www.idtdna.com).  The sequences are as follows: Wnt5a (+262/+340), sense 5′- 
GACCACATGCAGTACATCGGAGAAG -3′ and antisense 5′- TCCACCCTCGATG 
TCGGAATTG-3′; L7a (+145/+208), sense 5′-TTTGG CATTGGACAGGACATCC -3′ 
and antisense 5′-AGCGGGGCCATTT CACAAAG -3′. 
Immunofluorescent staining  
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Cells were seeded and grown on cover slips in 6-well plates pre-coated with 
fibronectin. After 2-d incubation, cells were washed three times with PBS, fixed with 4% 
paraformaldehyde at room temperature for 30 min and washed with PBS. Fixed cells 
were then incubated in PBS containing 0.1% Triton X-100 at room temperature for 15 
min and washed with PBS. Cover slips with cells were transferred onto slides and 
blocked with Image-iT ™ FX Signal Enhancer (I36933, Invitrogen) for 30 min at room 
temperature.  Slides were then incubated in PBS containing primary antibodies (1:150 
dilution) at 37°C for 2 h, followed by 3 PBS washing, and then incubated with Alexa 
Fluor 647 goat anti-rabbit IgG (1:200, A-21245, Invitrogen) for 45 min in the dark. 
Nuclei were stained with 1 µmol/L Hoechst 33342 (H3570, Invitrogen) for 15 min in the 
dark. Approximately 120 µL ProLong Gold Antifade Reagent (P36934, Invitrogen) was 
added to PBS-washed and drained slide. Slides were kept in the dark at room temperature 
for 24 h for the ProLong Gold to cure and stored at 4°C until analysis.  Images were 
acquired by fluorescence microscope (Zeiss Axiovert 200M with the Apotome). The 
primary antibodies used are as follows: Wnt5a, sc-30224 (Santa Cruz) and β-catenin, 
9587 (cell signaling). The quantification of immunofluorescent staining was performed 
by AxioVision 4.7 software after image acquisition. More than 20 cells (stained in red) in 
each slide were randomly chosen and the outline of each cell was drawn. The intensity 
per pixel of each selected cell was automatically generated by the software. Finally, the 
relative intensity per pixel in each group was calculated. 
Chromatin immunoprecipitation (ChIP)   
To determine the specific histone modifications related to the regulation of Wnt5a 
gene expression, ChIP analysis was performed according to a published protocol [79].  




 cells per 150 mm dish were plated.  Three dishes of cells were 
used for one treatment and sampling.  After treatment, cells were cross-linked with 1% 
formaldehyde for 10 min on a rotator at room temperature.  Cell pellets were resuspended 
in nuclei swelling buffer (5 mmol/L pipes pH 8.0, 85 mmol/L KCl, 0.5 % NP40) and 
lysed in SDS lysis buffer (50 mmol/L Tris-HCl pH 8.1, 10 mmol/L EDTA, 1% SDS) 
containing protease inhibitors and phosphatase inhibitors.  The chromatin was sonicated 
on ice using Sonic Dismembrator (model F100, Fisher Scientific) with power set at 5 for 
5 bursts of 40 s each.  Sheared chromatin was diluted with ChIP dilution buffer, aliquoted 
to 1 mL per antibody and incubated overnight with 2 µg of antibody/mL.  The chromatin-
antibody complex was precipitated with 60 µL of 50% (v/v) pre-blocked protein G-
agarose slurry (Millipore).  Normal rabbit IgG was used as the negative control.  
Supernatant from the normal rabbit IgG was saved as the input for total genomic DNA.  
Agarose with bound antibody was washed sequentially with 1 mL of the following 
solutions: low salt (20 mmol/L pH 8.0 Tris-HCl, 0.1% SDS, 2 mmol/L EDTA, 150 
mmol/L NaCl, 1% triton X-100), high salt (20 mmol/L pH 8.0 Tris-HCl, 0.1% SDS, 2 
mmol/L EDTA, 500 mmol/L NaCl, 1% triton X-100), LiCl (10 mmol/L pH 8.0 Tris-HCl, 
0.25 mmol/L LiCl, 1% NP40, 1 mmol/L EDTA, 1% sodium deoxycholate) , and TE (pH 
8.0).  Chromatin complexes were eluted twice with 250 µL of the elution buffer (1% SDS 
and 50 mmol/L NaHCO3) at 37C for 15 min and reversed-crosslinked with 0.2 mol/L 
NaCl at 65C for 5 h. Chromatin DNA was purified using QiaPrep miniprep kit (Qiagen) 
after proteinase K digestion . Immunoprecipitated DNA was detected by real time PCR 
using primers targeting different regions of the Wnt5a gene: promoter region (-96/-22), 
sense 5′-GGTCTTTTGCACAATCACGCC -3′ and antisense 5′- 
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TTTCCAACGTCCATCAGCGAC -3′; coding region (+6424/+6495), sense 5′- 
GATGGCTGGAAGTGCAATGTCT-3′ and antisense 5′- 
ACCTGGGCGAAGGAGAAAAA-3′. The antibodies used are as follows: Acetylated 
histone H3 (H3Ac, 06-599, Millipore), acetylated histone H4 (H4Ac, 06-866, Millipore), 
dimethyl-histone H3 lysine 4 (H3K4me2, 07-030, Millipore), trimethyl-histone H3 lysine 
9 (H3K9me3, 07-442, Millipore), trimethyl-histone H3 lysine 27 (H3K27me3, 07-449, 
Millipore), normal rabbit IgG (IgG, sc-2027, Santa Cruz Biotechnologies, Santa Cruz, 
CA), phosphorylated histone H3 serine 10 (pH3S10, sc-8656R, Santa Cruz). 
Adhesion assay 
Fibronectin-coated 96-well plates were used for the cell adhesion assay. For coating, 
plates were incubated with 0.3 µg fibronectin at 37 C for 1 h.  Plates were blocked with 
blocking buffer (0.5% BSA in MEM) at 37 C for 1 h. Then, 0.02×106 cells were plated 
and incubated in a cell culture incubator for 30 min.  Cells were fixed with 4% 
paraformaldehyde and then stained with crystal violet (5 mg/mL in 2% ethanol) for 10 
min and washed with water.  Fifty µL of 2% SDS was added to air-dried wells and 
incubated at room temperature for 30 min.  The plate was read at 562 nm in a microplate 
reader ELx800 (BioTek, Winooski, VT).  Values of absorbance obtained at wavelength 
562 nm represented relative amount of adherent cells.  
Statistical analysis 
Unpaired two-tailed Student’s t test was performed for mRNA expression. Two-way 
ANOVA using LSMeans was performed for ChIP results (SAS Institute Inc., Cary, NC). 
Two-way ANOVA using tukey was performed for adhesion results and 
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immunofluorescent staining quantification. Data are presented as the mean ± Standard 






























































Figure 4.1 Protein and mRNA expression of Wnt5a in non-metastatic human colon cancer cell line SW480 
and highly metastatic cell line SW620. a. Relative mRNA expression of Wnt5a in SW480 and SW620 
presented as the ratio to the L7a housekeeping gene (n=3).  mRNA was analyzed using real-time PCR.  
The values are presented as the mean ± SEM, *p<0.05 when comparing SW620 to SW480. b. Wnt5a 
protein expression in SW480 and SW620 using immunofluorescent staining.  Wnt5a protein was analyzed 
after immunofluorescent staining using an antibody against Wnt5a and an Alexa Fluor 647-labeled 
secondary antibody (red).  The cover slips were also counterstained with Hoechst 33342 fluorescent stain 
to detect the nucleus (blue).  The two pictures were overlaid to show Wnt5a staining on top of the nuclear 
staining (merged). c. Quantification of immunofluorescent staining of Wnt5a (stained in red) in SW480 
and SW620. Over twenty cells per slide were randomly chosen for quantification. Data was shown as 
relative intensity per pixel based on AxioVision4.7 software. The values are presented as the mean ± SEM, 
*p<0.05 when comparing SW620 to SW480.   
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Figure 4.2 Expression of Wnt5a mRNA after 5-aza-cytidine (Azacitidine), 
trichostatin A (TSA) and sodium butyrate (NaBt) treatment. a. Relative Wnt5a 
mRNA level was tested in SW620 treated with Azacitidine (0, 4 and 8 μmol/L) for 
48 h. mRNA was analyzed using real-time PCR and presented as the ratio to L7a 
(n=3).  b. Wnt5a mRNA level was tested in SW620 treated with TSA (50 and100 
nmol/L) or NaBt (2.5, 5 mmol/L) for 48 h. mRNA was analyzed using real-time 
PCR and presented as the ratio to L7a (n=3).  The values are presented as the mean 
































































































Figure 4.3 ChIP analysis of chromatin modifications in SW480 and SW620 a. Histone modifications 
at the human Wnt5a promoter region (-96/-22, upper panel) and coding region (+6424/+6495, lower 
panel) in SW480 and SW620 tested by ChIP (n=3).  Data is shown as a ratio to input DNA.  The 
values are presented as the mean ± SEM. *p<0.05 indicates statistical significance compared to 
SW480.  b. Histone modifications at the human Wnt5a promoter region (-96/-22, upper panel) and 
coding region (+6424/+6495, lower panel) in SW620 after NaBt exposure (5 mmol/L) for 48h tested 
by ChIP (n=3). Data is shown as a ratio to the input DNA. The values are presented as relative mean 
± SEM.  *p<0.05 when comparing to the non-treated SW620 control group. 
 














































Figure 4.4 Influence of NaBt treatment on the WNT signaling pathway and cell adhesion ability of 
SW620. a. Expression of β-catenin protein in SW480, SW620 and SW620 treated with NaBt (5 
mmol/L) for 48h using immunofluorescence.  β-catenin protein was analyzed by immunofluorescent 
staining using an antibody against β-catenin and an Alexa Fluor 647-labeled secondary antibody 
(red).  The cover slips were also counterstained with Hoechst 33342 fluorescent stain to detect the 
nucleus (blue).  The two pictures were overlaid to show β-catenin staining on top of the nuclear 
staining (merged).  b. Quantification of immunofluorescent staining of β-catenin protein (stained in 
red) in SW480, SW620 and SW620 treated with NaBt (shown in Fig.4a). Over twenty cells per slide 
were randomly chosen for quantification. Data was shown as relative intensity per pixel based on 
AxioVision4.7 software. The letters were assigned according to two-way ANOVA analysis using 
tukey. The values are presented as the mean ± SEM. Different letters indicate significant difference 
between groups (p<0.05). c. Cell adhesion ability of SW480, SW620 and SW620 treated with NaBt 
(5 mmol/L) for 48h (n=3).  Cells grown on fibronectin-coated plates were fixed and stained with 
crystal violet. The numbers of adherent cells were estimated by absorbance reading at 562 nm.  The 
letters were assigned according to two-way ANOVA analysis using tukey.  The values are presented 
as the mean ± SEM. Different letters indicate significant difference between groups (p<0.05). 
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CHAPTER 5 
Genistein decreased the progression of metastatic human colon cancer cells and 




This study tested the hypothesis that genistein (Gen), a soy isoflavone, represses 
colon cancer metastasis by modifying the expression of metastasis suppressor NDRG1. 
SW480 and SW620, which are primary and metastatic human colon cancer cell lines, 
respectively, were used. Gen treatment reduced the proliferation and migration of both 
cell lines. Gen specifically increased the adhesion of SW620, which was correlated to the 
increased expression of E-cadherin and the decreased matrix metalloproteinases-7. Gen 
caused global decrease of H3S10p in SW620, which was associated with the reduced 
proliferation. Moreover, Gen increased mRNA expression of NDRG1, a metastatic 
suppressor, and its transcriptional activity, and altered histone modifications at specific 
regions on the gene. Analysis of the activating histone mark H3K4me3 showed highly 
coordinated marking of the active transcription at the promoter region of NDRG1 in 
SW480 and further induction by Gen in the same regions.  On the other hand, SW480 
exhibits very little marking by the suppressive histone modification H3K27me3 but 
SW620, with the silenced NDRG1 expression, showed higher levels of the H3K27me3 in 
the downstream gene regions tested.  H3K36me3, a histone marker for transcriptional 
activation, also exhibited the marking of the actively transcribing gene in SW480 at the 
wnstream regions of the gene; whereas Gen treatment increased H3K36me3 in 
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SW620. In conclusion, Gen reduced the invasiveness of metastatic colon cancer cells by 
up-regulating the expression of NDRG1 gene, likely by changing histone modifications 
on the gene. 
Introduction 
 
Colorectal cancer (CRC) is the second most death-leading cancer in the US with 
incidence rate of about 140,000 and death rate more than 50,000 every year in the US 
[80, 107]. Five-year survival rate slumped from 89.9% to 11.9% when the localized 
primary cancer metastasizes to distant sites [1]. Metastasis is the ultimate cause of death 
from cancer. It is a complex process and involves multi-steps, including the detachment 
of primary cancer cells from local microenvironment, invading into the vasculature, and 
finally invading and growing in distant sites [21]. The poor prognosis of metastatic colon 
cancer is attributable to the lack of clinical interventions to reduce metastasis.  
Genistein (Gen), a biologically active isoflavone highly present in soy, has been 
consistently shown to reduce metastases in different types of cancer. The effect and 
mechanism of the anti-metastatic activities of Gen have been mostly studied in prostate 
and breast cancers. For example, in a murine prostate cancer metastasis model, 
metastases were decreased by 96% in mice fed with Gen at concentrations similar to the 
levels measured in Gen-consuming men [108].  In a postsurgical xenograft murine model 
of breast cancer metastasis, Gen reduced the lung metastasis by 10-fold [109]. Evidence 
also indicated that Gen repressed the metastasis of pancreatic cancer [110] and bladder 
cancer [111]. For colon cancer, Gen significantly reduced lung metastasis by 44% in vitro 
[18]; whereas in this study, the anti-metastatic function of Gen was mainly attributed to 
its antioxidant activity. The studies of prostate and breast cancer metastasis have shown 
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that Gen reduced cancer metastasis due to its ability to regulate various steps of the 
metastatic cascade, including cell adhesion, migration, invasion and angiogenesis [20, 
112]. Nevertheless, the effect and mechanism of anti-metastatic activities of Gen for 
colon cancer have yet been well understood.  
Gen has been shown to play an important role in epigenome modulation during 
cancer development and progression. Epigenetic modifications, mainly DNA methylation 
and histone modifications of cancer-related genes are associated with the anti-cancer 
and/or anti-metastasis activities of Gen in prostate cancer [113, 114], breast cancer [115], 
and colon cancer [116-118]. Time-dependent induction of Wnt5a by Gen in colon cancer 
cell SW1116 was consistent with the decreased methylation of CpGs at its promoter [57]. 
One of our publications indicated that Gen up-regulated the expression of DKK1 in colon 
cancer cell line SW480 and HCT15 and induced histone H3 acetylation of the gene at 
promoter region [117]. Gen-induced tumor suppressor genes p21 and p16 were correlated 
with the increased acetylated histones H3, H4, and dimethylated histone H3 lysine 4 at 
the p21 and p16 transcription start sites in metastatic human prostate cancer cell lines 
[114].  
NDRG1 (also known as cap43/rit42/RTP/Drg1/TDD5) is one of the validated 
metastasis suppressors (MS), which are molecules that inhibit the process of metastasis 
[119]. Previous study from our laboratory showed that the expression of NDRG1 was 
much lower in highly metastatic human colon cancer cell line SW620 than the primary 
colon cancer cell line, SW480 [8]. Our study also revealed that the transcriptional down-
regulation of NDRG1 in SW620 was associated with specific histone modifications at the 
promoter region of the gene. Therefore, the objective of the current study was to test the 
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hypothesis that Gen suppressed metastatic cascades through epigenetic modifications of 
NDRG1. We found that various cellular properties of SW480 and SW620 were changed 
by Gen at different degrees. Gen significantly affected the expression of NDRG1 in 
SW620, which was in correspondence with changes of histone modifications.  
Results 
Genistein changed the phenotype of SW480 and SW620, including morphology, 
proliferation, migration and invasion  
In order to test the effect of Gen on cellular properties related to colon cancer cell 
progression, cell morphology, proliferation, migration and invasion of both SW480 and 
SW620 with control DMSO and Gen treatments were measured.  Results showed that 
round-shaped SW620 was transformed to spindle shape by Gen, resembling that of 
SW480 (Figure 5.1a).  Cell proliferation was studied by WST-1 assay. Gen treatment 
significantly decreased the proliferation of SW480 and SW620 by ~20% and 60%, 
respectively (Figure 5.1b), suggesting that Gen affected cell proliferation, especially in 
metastatic cell line SW620. 
Gen also decreased the invasiveness of both SW480 and SW620 (Figure 5.1c).  After 
72 h, the number of cells that passed through collagen-coated Transwell inserts greatly 
decreased in Gen group compared to the control group for both SW480 and SW620.  It is 
also noteworthy that there were much more SW620 cells invaded through the Transwell 
inserts than SW480, confirming its metastatic potential (Figure 5.1c).   
Cell migration was measured by wound-healing assay. For SW480, in the control 
group, the wound completely healed in 48 h after the wound was made; but in Gen group, 
the wound did not heal, indicating that Gen inhibited the migration ability of SW480 
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(Figure 5.1d).  For SW620, Gen treatment also reduced the wound-healing rate, although 
the effect was not as significant as for SW480 (Figure 5.1e).   
Therefore, the overall metastatic progression of both the primary colon cancer cell 
line SW480 and metastatic SW620 were inhibited by Gen. But the effects of Gen 
treatment on different cellular properties varied between the two cell lines.  
Genistein enhanced the cell adhesion of SW620 but not SW480, which was 
correlated with altered gene expression of adhesion molecules 
As the disturbance of the integrity of intercellular junctions and cell-matrix adhesion 
is associated with cancer metastasis [120, 121], we measured how Gen changed the 
adhesion of both SW480 and SW620. Results showed that for both laminine- and 
fibronectin-coated plates, Gen treatment increased the adhesion capacity of highly 
metastatic cancer cell SW620 2-3 folds but did not change the adhesion of primary cancer 
cell SW480 (Figure 5.2a).  This observation indicated that Gen enhanced cell-matrix 
interaction in highly invasive cancer cells, which may lead to decreased cell invasiveness.  
In order to understand the molecular mechanism related to enhanced cell-matrix 
adhesion by Gen treatment, mRNA expression of cell adhesion-related genes were tested 
by real-time PCR. mRNA expression of CDH1 gene, which encodes one of the most 
important cell adhesion molecules E-cadherin [120], was increased ~3 times in SW620 
by Gen (Figure 5.2b). The up-regulation of CDH1 in SW620 was accompanied by the 
enhancement of cell adhesion. Interestingly, Gen reduced the expression of CDH1 by 
50% in the primary colon cancer cell line SW480. 
Matrix metalloproteinase (MMP) family is a group of enzymes that degrade 
extracellular matrix and therefore promotes tumor growth [122].  Analysis of gene 
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expression of selected MMPs from the present study showed that mRNA expression of 
MMP-7 was three times higher in SW620 than SW480, and Gen treatment caused ~50% 
decrease of MMP-7 expression in both SW480 and SW620 (Figure 5.2c). The decreasing 
trend of gelatinase A, MMP-2, was also shown in our study (Figure 5.2c). However, 
gelatinase B, MMP-9, was up-regulated by Gen in SW620 (Figure 5.2c). 
Genistein increased the transcription of NDRG1, a metastasis suppressor gene 
To investigate molecular mechanism of metastasis, we tested mRNA expression of 
NDRG1, which is reported as a metastasis suppressor gene [3], by real-time PCR (Figure 
5.3a). Consistent with our previous publication [68], NDRG1 mRNA expression was 
much lower in metastatic cell line SW620 than that of the non-metastatic SW480.  
Importantly, Gen treatment increased the NDRG1 mRNA levels more than 2 times in 
SW480 and ~8 times in SW620.  
The abundance of RNA polymerase II (Pol II) at gene promoter region is an indicator 
of the level of transcriptional initiation [123]. We measured the binding of Pol II at the 
promoter of NDRG1 by ChIP.  In accordance to the lower mRNA level for NDRG1 in 
SW620 comparing to SW480, transcriptional initiation is also markedly lower in SW620 
comparing to that in SW480, as indicated by the lower Pol II binding at the NDRG1 
promoter (DMSO groups, Figure 5.3b).  Two-d Gen induced a 2-fold increase in Pol II 
binding in both SW480 and SW620 (Figure 5.3b). We also measured the transcriptional 
rate of NDRG1 by measuring the level of premature mRNA formation by real-time PCR 
[124]. Similar to the mRNA expression and Pol II binding at promoter region, 
transcriptional rate of NDRG1 was induced by Gen in both SW480 and SW620 (Figure 
5.3c).  
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Increased expression of NDRG1 gene by Gen is associated with modified chromatin 
structures  
Our published study has shown that NDRG1 is transcriptionally regulated by histone 
modifications [8]. In the current study, we aimed at further answering the question that 
whether Gen-induced NDRG1 up-regulation is correlated with specific histone markers 
after the aforementioned changes in cellular physiology by Gen.  
ChIP assay was performed to analyze histone modifications at different gene regions 
of NDRG1 with control (DMSO) or Gen treatment in both SW480 and SW620. Primers 
were designed to cover gene regions from 5-upstream region to the last exon, exon 15 
(Figure 5.4a).   
We investigated the phosphorylation of histone H3 serine10 (H3S10p). H3S10p in 
SW480 was significantly lower than that in SW620 at all gene regions of NDRG1 tested 
(Figure 5.4b, dotted lines).  Furthermore, Gen decreased H3S10p in the entire NDRG1 
gene in SW620 (Figure 5.4b, SW620 Gen, solid line with symbol ) to the level of 
H3S10p observed in SW480.  To test specificity of the decreased H3S10p by Gen, we 
also measured the abundance of H3S10p at the promoter region of a housekeeping gene 
L7a (Figure 5.4c). Results showed that this modification in SW620 DMSO was 
significantly higher than SW480 DMSO and that Gen treatment significantly reduced the 
phosphorylation level of H3S10 in SW620. Hence, these results indicated that there is an 
overall higher level of phosphorylation at H3S10 in metastatic cells comparing to the 
primary colon cancer cell line and Gen treatment seemed to cause a global decrease of 
H3S10p in SW620.   
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Tri-methylation of histone H3 lysine4 (H3K4me3), a marker of transcriptional 
activation [125], was significantly higher in SW480 than in SW620 at all proximal 
promoter regions tested, i.e. +300, +1200 and +1500 (Figure 5.5, upper panel), 
corresponding to the higher transcriptional activity of the NDRG1 gene in SW480. In 
SW480, Gen treatment further induced trimethylation of H3K4 at proximal promoter 
regions at -600 and -50, also correlated with the induced gene expression in SW480. On 
the other hand, Gen did not change the level of H3K4me3 at any gene regions in SW620, 
suggesting that H3K4me3 may not specifically be responsible for the induced NDRG1 
expression by Gen in SW620.   
Tri-methylation of histone H3 lysine 27 (H3K27me3) is a hallmark of transcriptional 
repression [126]. H3K27me3 at coding regions +1200 and +1500 were higher in SW620 
than SW480 (Figure 5.5, lower panel), which was in correspondence with the lower 
expression of NDRG1 in SW620. Gen treatment specifically induced H3K27me3 at -2kb 
in SW620. Different abundance of H3K4me3 and H3K27me3 between these two cell 
lines is consistent with the known functions implicated in transcriptional regulation. 
However, neither modifications was associated with the Gen-induced NDRG1 expression 
in SW620.  These data indicate that H3K4me3 and H3K27me3 may be used for marking 
transcriptional activities for NDRG1 gene in the two cell lines but they may not be the 
histone modifications that are directly affected by Gen treatment.   
Tri-methylation of histone H3 lysine 36 (H3K36me3) is linked to active gene 
transcription and levels of this modification were increased toward the 3′ downstream 
region of actively transcribing genes [127]. In the current study, ChIP analysis of 
H3K36me3 showed a general increase by Gen in both SW480 and SW620 toward 3′ end 
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of NDRG1 gene. Gen also increased H3K36me3 at upstream of promoter (-2 kb and -1 
kb regions) in SW620 (Figure 5.6). Up-regulation of NDRG1 by Gen in both SW480 and 
SW620 was correlated to the increased H3K36me3, suggesting that Gen may exert the 
effect of transcriptional induction through enhancing H3K36me3 at specific gene regions 
of NDRG1.   
Discussion 
The current study, to our knowledge, is the first focusing on the effect of soy 
genistein on colon cancer metastasis and in particular, the epigenetic mechanisms 
involved in the anti-metastatic activity. Our findings indicated that Gen suppressed 
proliferation, invasiveness of the metastatic colon cancer cell line SW620 and altered the 
cell-matrix interaction. These metastatic-suppressing effects by Gen are associated with 
the increased expression of a key metastasis suppressor gene, NDRG1, likely through 
changes of histone modifications at specific regions of the gene. 
Although numerous studies have shown that Gen changed cellular properties of 
cancer cells, including decreasing proliferation [117, 128] and inhibiting cell migration 
[129], our study focused on comparing differential impacts of Gen on primary and 
metastatic colon cancer cells. Round-shaped SW620 cells, which possess characteristics 
of metastatic cells, were transformed to spindle shapes by Gen, suggesting that the 
metastatic ability of SW620 might be reduced after Gen treatment. The morphological 
change of SW620 by Gen was also correlated with the decreased invasiveness of the cells 
tested by invasion assay, which mimicked the step when cells penetrate extracellular 
matrix during metastatic process. Cell migration refers to the movement of individual 
cells, cell sheets and clusters from one location to another. It is central to cancer 
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progression. In our study, reduced cell migration by Gen indicated slower cell movement 
of both primary and metastatic colon cancer cells.  More importantly, the adhesion ability 
of SW620 was increased after Gen treatment; while the adhesion of SW480 did not 
change after the treatment. Because metastasis is usually associated with low cell 
adhesion, increased adhesion of SW620 by Gen may, in part, be responsible for the 
decreased invasiveness of the cells observed in the study. Our results are consistent with 
an earlier publication by Bergan et al., which showed that Gen enhanced the adhesion of 
metastatic human prostate cancer PC-3 and breast cancer cell line MCF-7 [130].  The 
expression of CDH1 gene, which encodes E-cadherin, was increased in SW620 by Gen 
treatment which corresponds to enhanced cell adhesion in SW620, confirming the 
metastasis-suppressing effect of Gen. Matrix metalloproteinases (MMPs) play important 
roles in the degradation of extracellular matrix; and up-regulation of MMP family 
members, in some cases, are positively correlated with the stage of cancer [122, 131]. 
MMP7 was a matrilysin, whose ECM substrates include laminin, fibronectin, and non-
fibrillar collagens [122]. It has been implicated as a marker of colon cancer onset and 
progression to metastasis [132-134]. Gen has also been shown to down-regulate MMP7 
expression in breast cancer cell line HCC1395 [128].  Here we showed that Gen 
treatment significantly decreased the expression of MMP7 in SW620. Although MMP2 
and MMP9 are also generally considered to be responsible for cancer invasion and 
metastasis [135], we didn’t observe significant change of MMP2 expression in Gen 
group. Nevertheless, Different changes of MMP7 and MMP9 induced by Gen suggested 
that Gen regulated MMP family members in different ways. Further research needs to be 
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done to clarify specific mechanisms regulating individual MMP member instead of 
generalizing the effect of Gen upon the entire MMP family.  
Downregulation of NDRG1, a metastasis suppressor, is correlated with increased cell 
invasiveness [3] and shorter 5-year survival in colon cancer patients [6]. Our previous 
study revealed that NDRG1 was drastically suppressed in highly metastatic colon cancer 
cell SW620 compared to SW480, its counterpart cell line from primary tumor [8]. Here 
we showed that Gen treatment restored NDRG1 expression in SW620, which is 
correlated with the decreased cell invasion. Previously, we also found that NDRG1 plays 
a role in regulating cell adhesion, which was further confirmed by this current study, 
indicating that induced NDRG1 expression by Gen caused the changes of cell adhesion 
ability. Based on these findings, NDRG1 can be potentially used as a metastasis marker, 
whose expression level is negatively related to cell invasiveness while positively 
associated with cell adhesion. Gen specifically increased the adhesion and NDRG1 
expression in SW620 but not SW480, suggesting that Gen-induced adhesion might be 
attributable to increased NDRG1 in metastatic cells. Further study is needed to 
investigate the interaction between NDRG1 and Gen as well as the signaling pathways 
involved in the process.  
NDRG1 expression is subjected to epigenetic regulation, including histone 
modifications and DNA methylation [77]. However, because the expression of NDRG1 
was not directly regulated by DNA methylation of the gene [8], in the current study, we 
focused on potential effects of Gen treatment on the histone modifications of NDRG1 
gene.  We found that Gen changed methylation of lysine and phosphorylation of serine 
residues on histone H3 located at different gene regions of NDRG1.  Phosphorylation of 
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histone H3 serine 10 is generally associated with highly condensed chromosome during 
cell cycle progression [77, 136]. Along this line of investigation, we previously reported a 
decreased H3S10p status that was associated with the repressed proliferation and reduced 
colon neoplasia by genistein and genistein-containing soy protein diet [116]. In the 
current study, H3S10p was decreased at every gene regions tested in SW620 by Gen 
treatment, indicating a global, down-regulatory effect.  This suggested that genistein may 
exert its anti-metastasis effects by reducing phosphorylation of histone H3 at serine 10, 
causing a general down-regulation of proliferation and cell cycle progression. 
The patterns of H3K4me3 and H3K27me3 abundance on NDRG1 gene were 
observed to be different between SW480 and SW620 but were not changed by Gen 
treatment. It is clear that, as a marker for transcriptional activation, H3K4me3 mostly 
marks the promoter regions of actively transcribing genes and this mark, together with 
the required histone methyltransferases, facilitates transcriptional elongation by RNA 
polymerase II [137-139].  Results from the current study confirmed the promoter 
association of the H3K4me3 in SW480 which exhibits higher transcriptional activity of 
NDRG1 gene.  In SW480 with the transcriptionally activated NDRG1, the entire gene 
regions were devoid of H3K27me3. On the other hand, marking by H3K27me3 at 
downstream of the promoter region of the gene (intron 1-2) clearly outlined a repressed 
transcriptional status in SW620.  The fact that Gen treatment further increased the level 
of an activation mark H3K4me3 in SW480 but did not change the repressive H3K27me3 
mark in SW620 suggested that the derepression of the silenced transcription by Gen 
treatment is likely to be on a separate, activating histone modification.   
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The present study showed that the increased H3K36me3 toward 3 end of the gene 
was positively correlated with enhanced gene expression by Gen in both SW480 and 
SW620, potentially serving as a marker for gene activation by dietary treatments. 
H3K36me3 has been shown to be associated with actively transcribing genes and 
specifically enriched at the 3 downstream region of genes for maintenance of 
transcriptional elongation [140, 141].  This is clearly shown in SW480 where there is an 
active transcriptional activity for NDRG1 gene in both control and Gen treatment groups.  
It is also evident that in SW620 without Gen treatment where the transcription of the 
gene is repressed, the H3K36me3 mark is generally low cross the entire gene region.  
More importantly, our study presented a striking piece of evidence that Gen treatment is 
able to cause a significant increase of the H3K36me3 mark toward the 3 end of the 
NDRG1 gene, inducing a positive chromatin mark that is correlated with the induced 
NDRG1 expression.  This suggests a critical role of H3K36me3 in opening chromatin 
structure and a potential mechanism for diet-induced gene activation.   
In conclusion, this study provided strong evidence of genistein effects in preventing 
cancer metastasis.  The investigation also improved our understanding of epigenetic 
mechanisms involved in the anti-metastatic functions of genistein in colon cancer 
progression. Further in vivo studies are needed to investigate the potential use of genistein 
as a chemo-protective agent for reducing colon cancer metastasis. 
Materials and Methods 
Cell culture  
The human colon cancer cell lines SW480 and SW620 were purchased from ATCC 
(Manassas, VA). Minimum essential medium (MEM) were purchased from the Cell 
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Media Facility at the University of Illinois.  Unless otherwise mentioned, all general 
chemicals and laboratory supplies were obtained from Fisher Scientific 
(www.fishersci.com).  Cell culture ware was purchased from Sarstedt (Newton, NC). 
Both cell lines were cultured in growth medium MEM supplemented with 10% fetal 
bovine serum (FBS) and 1% antibiotic-antimycotic solution (ABAM) at 37 °C in a humid 
incubator with 5% CO2. All experiments were performed using cells with 2-6 passages. 
Cell line verification was routinely performed in the laboratory according to the 
guidelines by ATCC.  
Genistein treatment 
A stock of 75 mmol/L of Gen was prepared by dissolving Gen in DMSO.  Treatment 
medium at the concentration of 75 µmol/L was prepared fresh by diluting the Gen stock 
directly in the growth medium.  SW480 and SW620 cells were plated in 60 mm culture 
dish or 96-well plate with regular growth medium containing 10% FBS and 1% ABAM. 
After overnight incubation, cells were treated with 75 µmol/L Gen for 2 d. Treatment 
medium was replenished every 24 h. After Gen treatment, cells were kept in the original 
cell culture containers or trypsinized for following experiments. 
Cell proliferation analysis using WST-1 assay 
One hundred μL per well of SW480 and SW620 cells were plated in 96-well plate 
(2000 cells per well) and grown overnight, followed by 2 d of 75 µmol/L Gen treatment. 
Then, 10 μL of cell proliferation reagent WST-1 (Roche) was added to each well of the 
plate. At the same time, untreated SW480 and SW620 cells with a series of cell numbers 
were mixed with 10 μL of the WST-1 reagent to generate the standard curve for each cell 
line. Afterwards, the plate was incubated at 37 °C for 4 h to complete the WST-1 assay. 
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The plate was shaken thoroughly for 1 min and the absorbance of the samples was read at 
450 nm against reference wavelength at 630 nm by a microplate reader.  
Cell adhesion 
Standard 96-well plates were coated with 1µg fibronectin or laminine at 37 C for 1 
h.  After that, wells were blocked with blocking buffer (0.5% BSA in MEM) at 37 C for 
1 h.  Two-day Gen-treated SW480 or SW620 cells were trypsinized from its original 
culture wares, re-plated into the pre-coated 96-well plate and incubated in cell culture 
incubator for 30 min. Then cells were fixed with 4% paraformaldehyde and stained with 
crystal violet (5 mg/mL in 2% ethanol) for 10 min and washed with water. Fifty µL of 
2% SDS was added to air-dried wells and incubated at room temperature for 30 min. The 
plate was read at 562 nm in a microplate reader. Level of absorbance at 562 nm 
represents numbers of adherent cells.  
Invasion assay 
Invasion assay was performed following the manufacturer’s instruction (BD 
Biosciences) using the Invasion Chamber with 8 µm pore size (Cat. No. 3422). Briefly, 
inserts were coated with 1 g collagen at 37C for 1 h. SW480 and SW620 were then 
plated onto inserts at concentration of 4,000 cells/100 L regular  growth media. 
Meanwhile, growth media with 75 mol/L Gen or 0.1% DMSO (as control) were added 
to the bottom of wells. After 72 h incubation, inserts were moved out of the chamber. 
Non-invading cells and collagen on upper surface of the inserts were removed using 
cotton swabs. Cells that invaded through the pores onto the lower surface of the inserts 
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were fixed by cooled methanol for 10 min followed by crystal violet staining. The images 
were taken using inverted light microscope at 10 × magnification (Axiovert; Carl Zeiss). 
Cell migration assay 





, respectively. On the second day, wounds were made using sterile 100 uL pipette 
tips. Floating cells were washed by PBS right away and then fresh growth media with 75 
umol/L Gen or 0.1% DMSO (as control) was added to the wells. The wounds were 
examined using inversion light microscopy (Axiovert ×10; Carl Zeiss) at time 0, in 24h 
and 48h.  
Quantitative real-time PCR 
Cells were harvested using TriReagent (Sigma-Aldrich). Total RNAs were isolated 
following the manufacturer’s instructions. RNA concentrations were detected by 
spectrophotometer. cDNA was synthesized from total RNA using High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, Foster City, CA). cDNA was then 
analyzed by real-time PCR using 7300 real-time PCR system (Applied Biosystems) and 
amplicons were detected with SYBR Green. In each reaction, 25 ng of synthesized cDNA 
were used in a 20 µL volume containing 10 µL Perfecta SYBR Green fast master mix 
(2x, Quanta BioSciences) and 0.25 µmol/L of each primer. Real-time PCR was 
performed using the following program:  95C for 10 min, 40 cycles of 95 C for 15 s 
followed by 60 C for 1 min. A serially diluted cDNA sample was used in the same PCR 
reaction to generate a standard curve, based on which the quantity of the unknown 
samples was calculated. Standard curves with slope -3.10±0.20 and R
20.99 were 
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accepted.  Housekeeping gene L7a was used as an internal control gene to normalize 
obtained raw data.  PCR primers were synthesized by Integrated DNA Technologies.  
The sequences are as follows: NDRG1, sense 5′- GCTGGCTGAAATGCTTCCTGG -3′ 
and antisense 5′-TGCTCCTGTTCCCATGCCAA-3′; L7a, sense 5′-TTTGGCATTG 
GACAG GACATCC -3′ and antisense 5′-AGCGGGGCCATTTCACAAAG -3′; CDH1, 
sense 5′-CCTGAAAAGAGAGTGGAAGTGTCCG -3′ and antisense 5′- 
CTCCTGGGCAGTGTAGG ATGTGATT -3′; MMP2, sense 5′- 
GAATCCATGATGGAGAGG CAGACA -3′ and antisense 5′- 
TCAAAGGGGTATCCATCGCCAT -3′; MMP7, sense 5′- 
ACAGGTCTCGGAGGAGATGCTCAC-3′ and antisense 5′- 
ATCCCTAGACTGCTACCATC CGTCC -3′; MMP9, sense 5′- 
TGCCTTTGGACACGCACGA-3′ and antisense 5′- 
CAGTAGAAGCGGTCCTGGCAGA -3′; transcription activity of NDRG1, sense 5′- 
GGGTGCAGAAGGGACTAGGTGAGT -3′ and antisense 5′- 
GCAATCTCTCCGTTCCCAGACAC -3′.  
Chromatin immunoprecipitation (ChIP)   
SW480 and SW620 cells were plated in 150 mm culture dish with regular growth 
media containing 10% FBS and 1% ABAM. After overnight incubation, cells were 
treated with 75 µmol/L Gen or 0.1% DMSO (as control) for 4 d. Treatment media were 
replenished every 48 h. Cross-linking was completed by agitating the cells in 1% 
formaldehyde for 10 min on a rotator at room temperature. Cell pellets were resuspended 
in nuclei swelling buffer (5 mmol/L Pipes pH 8.0, 85 mmol/L KCl, 0.5 % NP40) and 
lysed in SDS lysis buffer (50 mmol/L Tris-HCl pH 8.1, 10 mmol/L EDTA, 1% SDS) 
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containing protease inhibitors. Chromatin was sonicated using Qsonica sonicator (model 
Q800RS) with 20 sec pulse and 40 sec interval for 90 cycles. Sheared chromatin was 
diluted to 10 mL with ChIP dilution buffer. Dynabeads
®  
Protein G beads (Life 
Technologies AS) were bound to each antibody of interest by incubating  1 µg of 
antibody with 450 µg beads (15 L volume of the suspension provided by the 
manufacturer) at room temperature in PBS-T (PBS with 0.02% Tween 20) for 1 hr. After 
washing away the excessive amount of unbound antibody, 750 µL of diluted and sheared 
chromatin solution was added to the beads and incubated at room temperature for 2 h to 
form chromatin-antibody-bead complex. Normal rabbit IgG was used as the negative 
control. Supernatant from the normal rabbit IgG was saved as the input. The magnetic 
beads were washed sequentially with 1 mL each of the following solutions: low salt (20 
mmol/L pH 8.0 Tris-HCl, 0.1% SDS, 2 mmol/L EDTA, 150 mmol/L NaCl, 1% triton X-
100), high salt (20 mmol/L pH 8.0 Tris-HCl, 0.1% SDS, 2 mmol/L EDTA, 500 mmol/L 
NaCl, 1% triton X-100), LiCl (10 mmol/L pH 8.0 Tris-HCl, 0.25 mmol/L LiCl, 1% 
NP40, 1 mmol/L EDTA, 1% sodium deoxycholate) and Tris-EDTA (pH 8.0). Chromatin 
complexes were eluted twice with 250 µL of the elution buffer (1% SDS and 50 mmol/L 
NaHCO3) at 37C for 15 min each and reversed-cross-linked with 0.2 mol/L NaCl at 
65C for 5 h.  Chromatin DNA was purified using QiaPrep miniprep kit (Qiagen) after 
proteinase K digestion.  Immunoprecipitated DNA was detected by real time PCR using 
primers targeting different regions of the NDRG1 gene: distal 5 upstream region (-
2562F, forward /-2495R, reverse), 5′- AGGATAACAGGCACACAGGCTGC -3′ and 5′- 
ATCTCTGGGAGCCATCCTGCTG -3′; -1 kb region (-1261F, forward/-1164R, reverse), 
5′- CGCGCGTGTGTGTCTGTGGA-3′ and 5′- GCCACCTGCCCAGCGTTGAA -3′; -
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600 nt (-654F, forward/-587R, reverse), 5′- GGTGGGCAAGATGGACGAGATT -3′ and 
5′- TCCGATTCTC GCCTTCCGTG -3′; promoter region, -50 nt (-48F/+27R), 5′- 
GCCTATAAAGTCGCCCTCCG -3′ and 5′- AACTGACGAGCTTCAGCACCA -3′; 
intron 1-2, +300 nt, (+338F/+416R), 5′- TTTGGGTGCAGACACCGCT -3′ and 5′- 
GGGAGATGAATGGGACCCTGT -3′; intron 1-2, +1200 nt, (+1205F/+1273R), 5′- 
AAACACGCTGTCACGCCTCTGT -3′ and 5′- TGGGTAAGGAACCGACCCACTAA -
3′; intron 1-2, +1500 nt, (+1422F/+1501R), 5′- TCAGAAGTCAGCCAGTGGCCAG -3′ 
and 5′- TAGGAGAAGGTCCCGTGCAGCT -3′; intron 3-4, +17 kb nt, 
(+17026F/+17123R), 5′-TCCTTCCCCTTCCTCATCCCGT -3′ and 5′-
CCTTCTCTCCCCTTGCCCGC -3′;  3-UTR, +58 kb (exon 15, +58655F/58725R), 5′- 
GCATCCTCTTCCATTAACCAGTG -3′ and 5′- TTGGCAGTTTGGTGTCTCTGAG -
3′. 
The antibodies used are as follows: normal rabbit IgG (IgG, sc-2027, Santa Cruz), 
RNA polymerase II (Pol II, CTD4H8, 05-623, Millipore), trimethyl histone H3 lysine 4 
(H3K4me3, 07-473, Millipore), trimethyl histone H3 lysine 27 (H3K27me3, 07-449, 
Millipore), phosphorylated histone H3 serine 10 (pH3S10, sc-8656R, Santa Cruz), 
trimethyl histone H3 lysine 36 (H3K36me3, ab9050, abcam). 
Statistical analysis 
Unpaired two-tailed Student’s t test was performed for mRNA expression, cell 
adhesion and cell proliferation unless mentioned differently in the figure legends. One-
way ANOVA using LSM was performed for ChIP results of individual histone 
modifications (SAS Institute Inc., Cary, NC). Data are presented as the mean ± Standard 
error of the means (SEM). The statistical significance was set at p<0.05. 






Figure 5.1 Gen affected the morphology, proliferation and invasiveness of SW480 and 
SW620. (a) Images of SW480 and SW620 with 2d treatment of DMSO (ctrl) or 75 µM Gen 
were taken under a regular microscope (×20 magnification). (b) Cell proliferation was 
measured by WST assay. Three independent cell samples were analyzed and presented as the 
mean  SEM.  * indicates statistical significance compared to ctrl in the same cell line 
(p<0.05). (c) Cell invasion assay were conducted on BD Invasion Chamber coated with 
collagen. After 72h Gen treatment, cells that were able to invade through insert were fixed by 
crystal violet shown purple in the images. Gen decreased the migration of SW480 (d) and 
SW620 (e). Cell migration was measured by wound-healing assay. A sterilized 100 µl tip was 
used to make a straight wound and removed cells were washed right away. Pictures were 
taken under brightfield (×20 magnification) 0 hr, 24 hr and 48 hr after the wound was made. 
















Figure 5.2 Gen modified cell adhesion and adhesion related gene 
expression. (a) cell adhesion assay.  Three independent cell 
samples were analyzed and presented as the mean  SEM. * p<0.5 
comparing to DMSO control (b) CDH1 mRNA expression was 
measured by real-time PCR. Data were normalized to internal 
control L7a. (c) MMP mRNA expression was measured by real-
time PCR. Data were normalized to internal control L7a. 
 



















Figure 5.3 Gen transcriptionally increased the expression of 
NDRG1. (a) NDRG1 mRNA expression was measured by real-
time PCR. Data were normalized to internal control L7a. (b) The 
abundance of RNA polymerase II (Pol II) at NDRG1 promoter 
region was measured by ChIP. Data were normalized to input. (c) 
Transcription activity of NDRG1 gene was measured by real-time 
PCR. Data were normalized to internal control L7a. Three 
independent cell samples were analyzed and presented as the mean 
 SEM. One-way ANOVA was used to compare four groups, i.e. 
SW480 DMSO, SW480 Gen, SW620 DMSO, SW620 Gen. Groups 
without any same letter were significantly different (p˂ 0.05). 
 



















Figure 5.4 ChIP analysis of H3S10p abundance at NDRG1 gene 
in SW480 and SW620 with ctrl and Gen treatment. (a) A 
schematic drawing of the regions analyzed. Arrows represent 
different gene regions tested by real-time PCR (positions are 
numbered).  (b) Line graph of H3S10p abundance at different 
regions of NDRG1. Immunoprecipitated DNA was detected by 
real time PCR. Four independent experiments were analyzed 
and presented as the mean  SEM.  At each region, One-way 
ANOVA was used to compare four groups, i.e. SW480 DMSO, 
SW480 Gen, SW620 DMSO, SW620 Gen. Symbols in line 
graphs indicate statistical differences  (p˂ 0.05) of one group 
from those with no symbol or a different type of symbols. (c) 
Bar graph of H3S10p abundance at promoter of NDRG1. 
Groups without any same letter were significantly different (p˂ 
0.05). 
 



















Figure 5.5 ChIP analysis of H3K4me3 and H3K27me3 in SW480 and 
SW620 with ctrl and Gen treatment. A. A schematic drawing of the 
regions analyzed. Arrows represent different gene regions tested by real-
time PCR (positions are numbered).  B. Line graph of H3K4me3 and 
H3K27me3 abundance at different regions of NDRG1. 
Immunoprecipitated DNA was detected by real time PCR. Four 
independent experiments were analyzed and presented as the mean  
SEM.  At each region, One-way ANOVA was used to compare four 
groups, i.e. SW480 DMSO, SW480 Gen, SW620 DMSO, SW620 Gen. 
Symbols in line graphs indicate statistical differences (p˂ 0.05) of one 
group from those with no symbol or a different type of symbols. 



















Figure 5.6 ChIP analysis of H3K36me3 in SW480 and SW620 with 
ctrl and Gen treatment. A. A schematic drawing of the regions 
analyzed. Arrows represent different gene regions tested by real-time 
PCR (positions are numbered).  B. Line graph of H3K36me3 
abundance at different regions of NDRG1. Immunoprecipitated DNA 
was detected by real time PCR. Four independent experiments were 
analyzed and presented as the mean  SEM.  At each region, unpaired 
two-tailed Student’s t test was used to compare between ctrl and Gen 
group in the same cell line. * indicates statistical significance of Gen 
group compared to ctrl (p<0.05) at one gene region. 
 
- 79 - 
 
CHAPTER 6 
Genistein reduced liver metastasis from colon cancer through regulating molecular 




This study aimed at investigating the effect of genistein (Gen) on liver metastases derived 
from colon cancer and the molecular mechanism behind. Male athymic nude mice were 
fed with western diet (W; calories%, fat 39%, carb 50%), W diet supplemented with 
100ppm Gen (GL) or 500ppm Gen (GH) . After 16 weeks, all the animals were 
intrasplenically injected with metastatic human colon cancer cells SW620 and sacrificed 
8 weeks later. GL and GH mice showed lower % liver metastases (50% and 27.3%) 
compared to W group (80% of mice with metastases). Pathological evaluations of 
representative liver sections from all animals showed no significant differences of liver 
metastases derived from injected SW620, such as metastases size, % of necrosis and 
mitotic index. mRNA expressions of metastasis-related human genes tested by real-time 
PCR also showed no differences of gene expression. However, proliferation index 
represented by pH3S10 positive cells in liver metastases in W group was higher than GL 
and GH groups. To further examine whether liver microenvironment was altered by 
dietary Gen, both histological and molecular measurements were conducted. The 
expression of both β-catenin (key intracellular mediator of the Wnt signaling pathway) 
and a metastasis suppressor NDRG1 were increased by dietary Gen in metastasis-free 
liver sections, suggesting the liver microenvironment was altered by Gen, which might be 
highly responsible for the lower metastasis incidence in liver in Gen treatment group.  
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Introduction 
Cancer metastasis is secondary to cancer development and yet it accounts for most 
cancer death.  Metastasis is the process by which primary tumors invade into and start to 
proliferate in a distant new site.  Simply, it involves the migration of primary tumors 
through the tumor stroma, intravasation into the vasculature, followed by the last step of 
“colonization” (Stafford et al., 2008).  Despite the recent and continuous improvements 
on diagnosis and treatments, more than 50% of colon and rectal cancers metastasize to 
liver, lung, and lymph nodes (Segal and Saltz, 2009).  Five year survival rate remains 
below 50% for patients with metastatic colon cancer.  Because cancer metastasis is one of 
the major steps in cancer development, it is subject to intense investigations for the 
prevention and treatment of cancer. 
Metastasis is a highly inefficient process [142]. This raises the question as to whether 
the tendency to metastasize and colonize in a specific secondary site  is largely 
determined by the identities of the genetic and epigenetic characteristics of primary 
cancer cell itself or by contributions from local microenvironment at the metastasis-
susceptible sites. 
Liver is the most frequent metastasis site for colon cancer, mostly because of direct 
blood circulation via portal veins and the porous nature of liver sinusoids [32]. 
Furthermore, homeostatic and physiological functions of liver make it susceptible to 
injuries.  The presence of background changes and undercurrent disease states affect the 
hepatic morphology, for example, caloric restriction, blood flow, food intake, timing and 
duration of exposure and etc. These factors can affect occurrence of nonproliferative as 
well as proliferative liver lesions in rodents [143].  
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Dietary factors are closely associated with development and progression of colon 
cancer. One promising candidate is genistein (Gen), a biologically active soy isoflavone, 
which has been shown to suppress metastasis in colon [18] and breast cancer [17] in vitro 
and/or in vivo.  Several epidemiological studies have demonstrated that the blood 
concentration of Gen in individuals on a high-soy diet is 100–1000 times higher than that 
of the low-soy diet consumers (i.e., those who had a Western red meat-based diet) [144]. 
Differences in blood Gen concentrations have been linked to various clinical outcomes. 
Population-based studies suggested the low Gen concentration was associated with many 
cancer types especially breast and prostate neoplasms [145-147]. Our previous in vitro 
study showed that at concentration of 75 µmol/L (~21 mg/kg diet) in culture media, 
invasion and migration of metastatic colon cancer cell SW620 were suppressed by Gen 
treatment (Chapter 5). Furthermore, Gen inhibits metastasis by regulating nearly every 
step of the metastatic cascade, including cell adhesion, migration, invasion and 
angiogenesis [17, 56]. However, in vivo study of the effect of genistein on colon cancer 
metastasis is lacking, which diminishes its potential as a therapeutic inhibitor of 
metastasis. 
A metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), is 
negatively correlated with tumor progression in multiple neoplasms [1, 3]. However, the 
precise molecular effects of NDRG1 remain unclear. Recent studies demonstrated that 
the function of NDRG1 during cancer metastasis was related to its regulatory effect on 
the epithelial-mesenchymal transition, a key initial step in metastasis, and the Wnt/β-
catenin pathway [148, 149].  
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The objective of the current study was to investigate the effect of Gen on colon 
cancer metastasis in vivo in order to increase our understanding of the impact of 
microenvironment of secondary sites on the progression of metastasis from both 
histological and molecular aspects. Our results indicated that diet supplemented with 500 
ppm of Gen significantly decreased the incidence of liver metastasis from colon cancer, 
accompanied by activation of β-catenin signaling and NDRG1 expression in hepatic 
sections and decreased proliferation index of metastasis in liver, suggesting the molecular 
signals in liver microenvironment were more affected by Gen than the primary invading 
colon cancer cells.      
Results 
High dosage of Genistein supplement reduced liver metastasis incidence 
The control diet in this study (W) is a high fat, high carbohydrate and low protein diet 
modified from AIN 76A diet in order to mimic the diet that is common in the Western 
countries.  Treatment groups were fed with control diet supplemented with low dose of 
Gen (100 mg/kg, GL) and high dose of Gen (500 mg/kg, GH), respectively. After 16 wks, 
cultured metastatic human colon cancer cells SW620 were injected into the spleen of all 
the animals.  BLI images of one representative animal at 2 wks, 5 wks and 7 wks after 
SW620 injection in each group were shown in figure 1. BLI was used to monitor the 
progression of tumors of each animal. 
Animals were sacrificed 8 wks after cancer cell injection.  Tumors on spleens and 
livers were closely checked at necropsy. Percentage of animals with liver metastasis in all 
animals was 80%, 50%, and 27.3% in W, GL, and GH groups, respectively (Table 1). 
Percentage of animals with liver metastasis in animals with primary tumors in spleen was 
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100%, 62.5%, and 42.9% in W, GL, and GH, respectively.  The reductions of liver 
metastasis incidence in GH group compared to W by both types of calculation were 
statistically significant (p˂0.05), indicating high dose Gen supplemented W diet 
significantly suppressed liver metastasis incidence.  
Body weight and food intake were monitored through the entire study. No difference 
of body weight between three groups was reported (p=0.82, Supplementary figure 1a). 
No significant difference of food intake was observed among three groups (p=0.08, 
Supplementary figure 1b). 
Gen concentration in mice serum was measured by LC/ES-MS according to a 
published protocol [150]. Gen was absent in animals in W group. In GL group, Gen 
concentration was around 0.5 pmol/uL serum. GH group reached 1.5 pmol/uL, which is 
three times as high as Gen concentration in GL (Supplementary figure 2).  
Liver metastases of three groups have similar characteristics  
To systematically evaluate pathological variables in metastases and in entire liver, a 
certified veterinary pathologist, who was blinded to the groups performed histologic 
evaluation of the liver tissue sections stained with H&E. 
Average tumor size of liver metastases in W, GL, and GH groups were 6.9, 2.1, 2.5 
mm
2
, respectively, but they were not significantly different from one another. However, 
W group had more big tumors than GL and GH groups (Figure 6.2a, Table 2). Tumor 
necrosis (TN), which is formed when tumors outgrow their blood supply, has been 
repeatedly associated with larger tumors, higher grade, and higher proliferative activity. It 
is generally regarded as an indirect indicator of biologically aggressive tumor behavior 
[151]. In the current study, the area of necrosis in each tumor was measured by image J 
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(Figure 6.2b). Average percentage of necrosis in its surrounding tumor was 41%, 42%, 
and 24% in W, GL and GH. Although necrotic areas in tumors were not different among 
groups, GH group had the smallest average percentage of TN.  Mitotic index (MI), which 
is defined as the sum of mitotic figures (MFs) per 10 consecutive high-power fields (HPF) 
in the area of the highest mitotic activity, was assessed to measure how fast cancer cells 
are dividing and growing. However, there was no difference of MI between groups 
(Table 2).  
 In addition to pathological assessment of metastasis/tumor, non-tumor parts of livers 
were also examined. To evaluate the hepatocellular vacuolation of lipid, hepatocellular 
glycogen content, and inflammation, a score ranging from 0 to 5 was given to each 
variable for each animal. The average score of hepatocellular vacuolation was 1.4, 1.6, 
and 1.5 for W, GL, and GH (Table 2). The mean glycogen scores of three groups were all 
equal or close to 2, suggesting that Gen supplementation in W diet did not cause 
significant changes of lipid or glycogen metabolism in liver. For inflammation, there was 
no indication by histological scores showing that western diet lead to severe 
inflammation. Neither did Gen supplementation significantly affect inflammation.  
To specifically test the gene expression of metastasis related genes in liver metastasis, 
which was comprised of human cancer cell SW620, human qPCR primers that only 
amplify mRNA of human genes but do not align with any sequence of the same gene in 
mouse were designed. The species-specificities of the primers were confirmed by testing 
the gene expression in mice without SW620 injection (negative control). Only primers 
that do not amplify human genes in the negative controls were included in the study. 
Expression of metastasis suppressor genes, NDRG1 and CDH1, prognostic biomarker of 
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different types of carcinoma, MACC1, and vascular endothelial growth factor VEGF, 
were tested. However, there was no significant difference of gene expression among W, 
GL and GH groups for all tested genes (Figure 6.3), suggesting that Gen did not cause a 
global change of developed metastases in liver at transcriptional level. This supports the 
similarities of most pathological variables of liver metastases in three treatment group.  
We also measured the percentage of apoptotic cells in liver metastases by Terminal 
deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL). There was no 
detectable difference of positive stained cells per field among W, GL and groups, 
suggesting Gen did not significantly change the progress of cell apoptosis in liver 
metastases (Figure 6.4). 
Overall, the examinations of liver metastases revealed little pathological and 
molecular difference between W and Gen groups.  
Gen groups showed lower pH3S10 proliferative index than W group only in liver 
metastases but not in normal liver 
In order to assess the proliferation index of SW620 cells in GH group, which showed 
lower liver metastasis incidence, we performed phosphorylated-histone H3 Serine 10 
(pH3S10) immunostaining (Figure 6.5). pH3S10 positive cells per 0.06 mm
2
 in liver 
metastases in W group was 13, which was about two times of the positive counts in GL 
and GH groups (p<0.05). This finding indicated that Gen supplementation repressed the 
proliferation of injected SW620 cancer cells in the livers of mice. Proliferation index in 
liver metastases was the only molecular indicator which was significantly changed by 
Gen, and the decreased proliferation index in Gen groups was correspondent with 
decreased metastasis incidence in those groups. 
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Molecular signaling in liver was influenced by Gen supplementation 
In order to further test whether reduced liver metastasis caused by dietary Gen was 
associated with altered  liver environment, where the injected colon cancer cells relocated 
and grew, the expression of beta-catenin and NDRG1, which were both shown to play 
important roles in malignant cancer progression were tested by immunofluorescence (IF). 
Aberrant beta-catenin signaling is common in malignant cancer [152]. The relative 
intensity of beta-catenin in GL and GH groups were nearly 15% higher than that in W 
group (p<0.5) (Figure 6.6). NDRG1 is a metastasis suppressor in colon cancer [3, 8]. 
However, recent studies have revealed the complex functions of NDRG1 in human 
hepatocellular carcinoma [153]. In the current study, to evaluate the molecular 
background of liver microenvironment that might be influenced by dietary Gen, the 
expression and distribution of NDRG1 were tested by IF and western blot. In non-tumor 
liver tissue sections, overall NDRG1 expression appeared to be more in GH groups than 
W and GL by IF (Figure 6.7a), which was further confirmed by western blot (Figure 
6.7b). Moreover, overexpression of NDRG1 was observed in the liver metastases from 
colon cancer (Figure 6.8), which was in accordance with studies that showed low 
expression of NDRG1 in normal liver but high in hepatocellular carcinoma [153]. 
Our findings demonstrated significant gene expression changes occur in the liver 
microenvironment by dietary Gen supplementation in W diet, suggesting that Gen might 
play an important role in modifying liver microenvironment to a less favorable site for 
colon cancer to seed and proliferate. 
Discussion 
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In the current study, we aim at answering the question whether the primary colon 
cancer cells or the liver microenvironment or both of them determine liver metastases 
from primary colon cancer. To our knowledge, this is the first research to create a 
modified liver microenvironment by dietary Gen supplementation and to reveal the 
impact of this change on colon cancer metastasis incidence in liver.  Our results showed 
500 ppm of Gen supplemented western diet significantly reduced the rate of liver 
metastasis from colon cancer. Decreased proliferation of liver metastasis was found to be 
associated with reduced metastasis incidence. Interestingly, modified molecular signaling 
was found in normal liver but not metastasis, suggesting modified liver 
microenvironment than colon cancer cells might be more responsible for the lower 
metastasis incidence in liver. 
Metastatic disease of the liver is a frequent event for patients with colorectal cancer 
and is a major cause of colorectal cancer-related death. Cancer cells, microenvironment, 
and the interactions between cancer cells and the microenvironment are crucial at many 
steps throughout the metastatic process and contribute to a high level of complexity of 
metastasis [25]. On one hand, extracellular factors in microenvironment may or may not 
allow cancer cells to metastasize; on the other hand, cancer cells alter the 
microenvironment directly (e.g., proteolytic cleavage of the ECM) or indirectly (e.g., 
induction of nearby cells to secrete proteases) [30].  
The components of diet in this study were well designed to better represent the diet of 
human populations in western world. High fat diet has been shown to increase colon 
cancer metastasis to liver in animal models by changing microenvironment of livers 
[154]. Therefore, we used high fat diet (calories%, fat 39%, carbohydrates 50%) as 
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control diet in this study in order to establish a permissive hepatic microenvironment for 
colon cancer metastasis. The dosage of Gen in treatment groups were determined based 
on published study and our previous findings. Holder et al. found that [155] total blood 
Gen ranged from <15 nM in animals fed soy-free control diet to as high as 8.9 μM in 
male rats fed 1250 μg of Gen/g of chow and encompassed blood isoflavone levels 
observed in humans consuming a typical Asian diet and nutritional supplements (0.1−1 
μM) and infants consuming soy formulas (2−7 μM), which were close to serum Gen 
concentration in our GL group (0.5 μM) and GH group (1.5 μM), respectively.  
One of the remarkable findings in our study was the significantly reduced liver 
metastasis by 500ppm Gen supplementation (Table 1), in that it is, to our knowledge, the 
first in vivo study to reveal the colorectal liver metastasis-suppressing function by oral 
intake of dietary Gen. In an experimental colon cancer metastasis mouse model [18], the 
i.p. injection of Gen caused 44% reduction of murine colon cancer metastasis to lung.  
However, the study was less valuable for human studies because of the missing 
information of dosage in the study and the inconvenience of i.p. method of delivery.  
A thorough pathological evaluation of liver sections of all the animals showed no 
significant difference of liver metastases derived from injected SW620, such as 
metastases size, % of necrosis and mitotic index (Table2, Figure 6.2). There was no 
detectable difference of human gene expression by real-time PCR using highly specific 
human primers (Figure 6.3). The only detected difference of liver metastases among three 
groups was proliferation index determined by pH3S10 immunostaining (Figure 6.5), 
indicating Gen reduced the proliferation of colorectal liver metastasis in vivo, which was 
in correspondence with decreased metastasis incidence in Gen treatment group. However, 
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most pathological variables and gene expression of metastasis-related genes were not 
affected by Gen intake.  
To further test the role of liver microenvironment on metastasis incidence and the 
impact of Gen on liver from the perspectives of liver biology and molecular mechanism, 
hepatocellular vacuolation of lipid, hepatocellular glycogen content, and inflammation 
were all evaluated. Soy protein isolate has been shown to significantly lower fat content 
in the liver of obese rats [156]. However, our results showed neither western diet induced 
lipid overload nor hepatic vacuolation of lipid and glycogen content were changed by 
dietary Gen. The inconsistency of these two studies might be related to different animal 
models, which vary in lipid metabolism.  
Aberrant Wnt signaling pathway and beta-catenin, the key intracellular mediator of 
the Wnt signaling pathway, have been related to the development and progression of 
various types of cancer. β-catenin expression is frequently altered in several 
malignancies, such as colorectal cancer [157], hepatocellular cancer [152], gastric cancer 
[158] and etc. A recent study indicated that β-catenin expression is frequently absent in 
liver metastases of gastric cancer [158]. β-catenin signaling plays important roles in liver 
development, liver regeneration and hepatocellular cancer development [152].  Its 
activation is observed sometimes in up to 90% of hepatocellular cancer (HCC), might in 
fact be exhibiting important role in maintaining hepatocyte function within tumors. It has 
been suggested that β-catenin signaling in the absence of β-catenin mutations in HCC 
within tumor nodules may be playing an important role in maintaining liver function in 
such patients [59]. In our current study, β-catenin expression was overexpressed by Gen 
in metastasis-free liver sections (Figure 6.6), which was in correspondence with another 
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study showing that dietary soy protein restored the β-catenin protein level in liver of 
high-fat diet induced obese rats [156]. Although unlike Zhou’s study, the induction of β-
catenin signaling in our study was not correlated with hepatic fat metabolism, it might be 
associated with β-catenin’s roles in liver development and liver regeneration [59]. 
Expression of NDRG1 is negatively correlated with the overall survival time for 
colorectal cancer patients with II tumor, node, metastasis system (TNM) stage disease 
and tumors [6]. It was proposed that suppression of colon cancer metastasis by NDRG1 
occurs by inducing colon cancer cell differentiation and partially reversing the metastatic 
phenotype [3]. In contrast, a pathological study drew the opposite conclusion, namely, 
that hepatocellular carcinomas express elevated levels of NDRG1 protein, a likely tumor 
marker [159]. Intriguingly, our results also revealed a significant higher expression of 
liver metastases than surrounding normal liver (Figure 6.8), even though the carcinomas 
was derived from injected colon cancer cells. We also found NDRG1 expression was up-
regulated in liver overall by Gen (Figure 6.7). This result resembles our finding of Gen-
induced NDRG1 overexpression in SW620 in vitro (Chapter 5). However, further 
investigation of specific molecular mechanisms of up-regulation of NDRG1by Gen in 
colon cancer cells and liver tissue would greatly contribute to our understanding of the 
function of NDRG1 in metastasis cascades. 
In general, the findings from our study suggested the molecular signaling in liver 
microenvironment may play an important role in the development of liver metastasis 
from colon cancer. This study provide information to set the foundation for further 
research about the interaction between primary colon cancer and liver microenvironment 
under the impact of dietary Gen. 
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Materials and Methods 
Animals 
Athymic male mice were fed with modified high fat AIN 76A diet (calories%, fat 
39%, carbohydrates 50%) after they were obtained from company. Body weight and food 
intake for each animal were measured once per week. One week later, two thirds of the 
animals were randomly split to two group and fed with low dose Genistein 
(GL,100mg/kg of high fat diet, aglycone equivalent) and high dose Genistein (GH, 
500mg/kg of high fat diet, aglycone equivalent) diet. There are 10 to 11 animals in each 
diet group. After 16 weeks, all the animals were intrasplenically injected with 2.5 million 
of luciferase gene transfected human colon cancer cell line SW620.  The incidence of 
cancer development in spleen and metastases in liver was monitored using BLI of 
luminescence once a week.  BLI was carried out using a custom made imaging system 
(Stanford Photonics, Palo Alto, CA), which includes a photon-tight box, bright field 
illumination, warming plate and a dual micro-channel plate ICCD camera (Mega 10-Z 
with cathode cooling). D-luciferin was freshly made as a 150mg/mL PBS solution before 
imaging. The dosage (μL) was calculated as 10×body weight (g) and injected 
intraperitoneally into each animal. Three minutes after the administration, the mouse was 
anesthetized using isoflurane/oxygen gas from a vaporizer and placed face-up on a 
height-adjustable tray in the imaging system for whole body imaging. General anesthesia 
was maintained throughout the imaging for each mouse. Photon emission was collected 
for a 3-minute period using imaging software Piper Control (Stanford Photonics, Palo 
Alto, CA). Animals were sacrificed 8 weeks after cancer cell injection. Mice were 
euthanized by exsanguination. Six representative sections of three lobes (left lateral lobe, 
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right and left median lobes) of liver from each mouse were sampled and fixed in 10% 
buffered formalin for histological analysis. The rest of the organs, whole blood and serum 
were frozen in liquid nitrogen for other experiments. 
Histological observation  
Formalin-fixed tissues were then cut and embedded in paraffin for microscopic 
investigation. The samples were cut into 5-μm-thick sections and stained with 
hematoxylin and eosin (H&E). Images were obtained using a NanoZoomer Slide Scanner 
and NDP View software. Ten x40 light microscopic fields were examined on each 
section for each mouse liver to obtain a representative view of the sample. All the slides 
were evaluated histologically by a certified veterinary pathologist. 
RNA isolation and real-time quantitative RT-PCR  
Frozen tissue samples from all the animals in each group were individually ground 
with a mortar and pestle in liquid nitrogen (around 20 mg liver tissues per animal). Total 
RNA from each animal was extracted from samples using TRI reagent (Sigma-Aldrich). 
cDNA was synthesized from 2 µg of total RNA using the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). cDNA was then detected with SYBR Green fast 
master mix (2x, Quanta BioSciences) by 7300 real-time PCR system (Applied 
Biosystems) at 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 
min. The amount of mRNA was quantified by comparing to a serially diluted cDNA 
standard created from the same RNA isolation. The sequences are as follows: hNDRG1, 
sense 5′-TTGGGAGGAGGAAGTAGTCCAGC -3′ and antisense 5′-
GGCGGCAGGTAACGAGTCATT-3′; hMACC1, sense 5′-
CTAGAAAGAGGGGAAGCAAGCACA -3′ and antisense 5′-
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TGAACTGAAGAGGTCAGGTGTGGA -3′; hVEGFa, sense 5′-
CTTGCCTTGCTGCTCTACCTCCA -3′ and antisense 5′-
ATTCTGCCCTCCTCCTTCTGCC -3′; hCDH1, sense 5′-
CCTGAAAAGAGAGTGGAAGTGTCCG -3′ and antisense 5′-
CTCCTGGGCAGTGTAGGATGTGATT -3′. Regions of cross homology between 
human and mouse were avoided while designing primers. Designed human gene primers 
were then BLASTed against the mouse transcript database to make sure there is no 
significant cross homologies for each gene. The above steps ensured that all the human 
primers only specifically amplified human genes but not the same genes in mouse. 
TUNEL 
Terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL) assay 
was used to label apoptotic nuclei in paraffin-embedded liver sections using ApopTag® 
Peroxidase In Situ Apoptosis Detection Kit (Millipore,S7100) following the instruction. 
Paraffin-embedded tissue slides were deparaffinized in xylene and rehydrated in ethanol, 
freshly diluted proteinase K (20ug/ml) was applied to the specimen for 15 mins at room 
temperature. Tissue sections were then quenched in 3.0% hydrogen peroxide in PBS for 
10 mins at room temperature to remove endogenous peroxidase. After that, slides were 
incubated with equilibration buffer for 1min, followed by an incubation of terminal 
deoxynucleotidyl transferase (TdT) at 37 °C for 1h to add nucleotides at 3'-OH ends of 
double-stranded or single-stranded DNA. The reaction was terminated by applying 
Stop/Wash buffer to slides. Anti-digoxigenin antibody was then incubated with tissue 
sections for 30 mins at room temperature to form digoxigenin-conjugated nucleotides.  
DAB was then added onto tissue sections to react with peroxidase molecule that is 
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conjugated on anti-digoxigenin antibody for detection. Negative control was performed 
without TdT enzyme. Positive control was incubated with DNase I for 10 mins at room 
temperature before TdT reaction. Images were obtained using aNanoZoomer Slide 
Scanner and NDP View software. Five ×40 light microscopic fields on the normal liver 
tissue part instead of tumor part were examined for five random animals per group. 
Positive cells per 0.4µm x 0.4 µm field were counted.  
Immunohistochemistry  
Briefly, paraffin-embedded tissue slides were deparaffinized, quenched in 3.0% 
hydrogen peroxide in PBS, and then boiled for 30 minutes in citrate buffer to retrieve 
antigens in tissue sections. Tissue slides were blocked with avidin and biotin for 15 mins 
each and then blocked with horse serum for half an hour. After that, primary anti-
phosphorylated histone H3 Serine 10 antibody (Santa Cruz, sc-8656-R) was applied to 
tissue sections and incubated for 2hrs at room temperature. After washing with PBS, SS 
Rabbit link (biogenex, HK336-9R) was added for 30 mins, followed by SS label 
incubation (biogenex, HK330-9K) for another 30 mins. To stain the nuclei of cells, slides 
were incubated in haematoxylin for 2 mins. After that, DAB reagent was applied 15 sec 
on tissue sections and washed away with running tap water. Negative control was 
performed without primary antibody. Images were obtained using a NanoZoomer Slide 
Scanner and NDP View software. Five × 40 light microscopic fields on the tumor parts 
were examined for animals with tumors. Positive cells per 0.06 mm
2
 field were counted.  
Immunofluorescent staining  
Frozen liver samples were embedded in Tissue-Tek OCT compound (VWR, Radnor, 
PA, USA) and cut to a thickness of 5 μm in a cryostat at −20°C. The sections were fixed 
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in 70% ethanol, permeabilized with 0.1% Triton X-100, blocked with Image-iT FX signal 
enhancer (Invitrogen) for 30 min, incubated with primary antibody (β-catenin, cat # 
9587S, Cell Signaling; or NDRG1, #N8539, Sigma-Aldrich) for 2 h at 37°C, and 
followed by an incubation of a goat anti-rabbit antibody (Alexa Fluor 647 1:200 dilution, 
Invitrogen) for 45 min in a dark chamber. The samples were counterstained with Hoechst 
33342 (Invitrogen) for 15 min and then washed with PBS. Coverslip was mounted on the 
sections using Prolong Gold antifade reagent (Invitrogen). Pictures were taken using the 
Axiovert 200M equipment (Zeiss) and Zeiss LSM 700 Confocal microscope. 
Western blotting analysis 
Frozen tissue samples from all the animals in each group were individually ground 
with a mortar and pestle in liquid nitrogen (around 20 mg liver tissues per animal), and 
then lysed by 500 µL lysis buffer (0.125 mol/L Tris–HCl,pH 6.8, 1% SDS, 0.04% 
bromophenol blue, and 20% glycerol, v/v ) with a proteinase inhibitor (Roche) and a 
phosphotase inhibitor cocktail (Sigma-Aldrich). Total protein was size-fractionated on a 
12% Tris–HCl polyacrylamide gel and transferred at 14 V onto a PVDF membrane (Bio-
Rad) at 4 C for 1 h. PVDF membranes were incubated with blocking solution containing 
10% (w/v) nonfat dry milk (NFDM), 20 mmol/L Tris–HCl with pH 7.6, 137 mmol/L 
NaCl, and 0.1% (v/v) Tween-20 for 1.5 h at room temperature. Antibody against NDRG1 
(N8539, Sigma-Aldrich) was diluted 1:1000 in 10% NFDM blocking solution and 
incubated at room temperature for 2h. Subsequently, the membranes were washed with 
blocking solution containing 5% NFDM for 5 x 5 min. Goat anti-rabbit HRP-conjugated 
secondary antibody was diluted 1:10000 in blocking solution containing 5% (w/v) 
NFDM and incubated for 1 h at room temperature. After washing 5x 5 min in blocking 
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solution containing 1% (w/v) NFDM, the membranes were exposed to the enhanced 
chemiluminescence reagent SuperSignal West Dura (Pierce). Signals were detected by 
ChemiDoc XRS imaging system (Bio-Rad). NDRG1 protein abundance was normalized 
to Lamin A protein amount. 
Statistical analysis 
One-way repeated-measures ANOVA was used as the statistical method for the body 
weight and food intake analysis. Comparisons of cancer incidence among W, GL and GH 
groups were evaluated with Fisher’s exact test. Unpaired two-tailed Student’s t test was 



















































Table 6.1 Liver metastasis incidence in W, GL and GH groups  
Table 6.2 Pathological variables of livers in W, GL and GH groups   

























Figure 6.1 Liver metastasis incidence. Pictures 
of bioluminescent imaging (BLI) of one 
representative animal in each group at 2, 5, and 
7 weeks after colon cancer cell injection, 
accompanied by the photos of liver and lung of 
the same animal after necropsy.  
 

























Figure 6.2 Scatter plot of tumor size and necrotic area of 
liver metastases. (A) Scatter plot of tumor size.  Each dot 
represents the size of maximum tumor in each animal 
with liver metastasis. The drawn bar represents the 
average of all the animals in each group (B) Scatter plot 
of % of necrotic area of liver metastases. Each dot 
represents the % of necrotic area of every single detetable 
tumor on H&E slides in each animal with liver 
metastasis. The drawn bar represents the average of all 
the tumors in each group. (C) Representative of pictures 
of liver metastasis taken under x40 light microscope. The 
outline of tumor and necrosis within the tumor was drawn 
by image J and the areas of both entire tumor and necrosis 
were automatically measured by the software. 
 

























Figure 6.3 Human NDRG1, CDH1, MACC1 and 
VEGFa mRNA expression measured by real-time 
RT-PCR. Primers highly specifically detect human 
gene expression without cross-species detection were 
used.  All the animal samples were analyzed and 
presented as the mean± SEM.   
 

























Figure 6.4 Quantification of TUNEL-
positive cells in liver metastases. Five 
×40 light microscopic fields on the 
normal liver tissue part instead of tumor 
part were examined for five random 
animals per group. Positive cells per 
0.06mm
2
 field were counted. 
 

























Figure 6.5 pH3S10 immunostaining of 
liver metastasis. (A) Quantification of 
pH3S10 positive cells/field in liver 
metastasis. Five ×40 light microscopic 
fields from tumor parts were examined for 
animals with tumors. Positive cells per 
0.06 mm
2
 field were counted, analyzed and 
positive counts were presented as the mean 
± SEM.  * indicates statistical significance 
compared to W (p<0.05). (B) 
Representative pictures of immunostaining 
for pH3S10 in liver metastasis of a 0.06 
mm
2
 field.  
 

























Figure 6.6 β-catenin immunofluorescence (IF) 
of metastasis-free liver sections. (A) 
Quantification of relative intensity of β-catenin 
signals. Five x20 pictures using the Axiovert 
200M equipment (Zeiss) of each animal were 
taken and qualified. (B) Representative IF 
images of one animal from each group. Cell 
nuclei were stained with Hoechst 33342 (blue), 
primary antibody was stained with Alexa Fluor 
647 (Red). Quantification of relative β-catenin 
intensity was presented as the mean ± SEM.  * 
indicates statistical significance compared to W 
(p<0.05). The scale bar represents 50 µm. 
 

























Figure 6.7 NDRG1 IF of metastasis-free liver sections. 
(A) Representative IF images of one animal from each 
group. Cell nuclei were stained with Hoechst 33342 
(blue), primary antibody was stained with Alexa Fluor 
647 (Red). Pictures were taken under x20 
magnification using Zeiss LSM 700 Confocal 
microscope. (B) Western blot analysis of NDRG1 
protein. Five animals randomly chosen from each 
group were tested, quantified and normalized to Lamin 
A protein. Data was presented as the mean ± SEM.  
Same letter was assigned to group with no statistically 
significant difference.  The scale bar represents 200 
µm. 
 

























Figure 6.8 NDRG1 IF of sections with 
liver metastases. Representative IF 
images of one animal from each 
group. Cell nuclei were stained with 
Hoechst 33342 (blue), primary 
antibody was stained with Alexa Fluor 
647 (Red). Pictures were taken under 
×20 magnification using Zeiss LSM 
700 Confocal microscope. The scale 
bar represents 200 µm. 
 

























Supplementary Figure 6.9 Body weight and food 
intake in athymic nude mice fed by western, 
genistein low and genistein high diets during the 25-
week-experiment. (A) The individual point 
represents the average of body weight in the diet 
group. Animals fed by these three diets showed a 
same trend of body weight growth throughout the 
whole experiment (p=0.82). (B) The individual point 
represents the average of food intake per day in the 
diet group. No difference of food intake was shown 
in the three different diet groups (p=0.08). 
 

























Supplementary Figure 6.10  Gen concentration 
in mice serum. Average concentration of all the 
animals in each group was analyzed and 
presented as the mean ± SEM.  * indicates 
statistical significance compared GH with GL 
(p<0.05). 
 





 There are three major findings from the current study: one, colon cancer metastasis is 
associated with aberrant epigenetic regulation of metastasis suppressor genes; two, 
genistein can epigenetically induce the expression of metastasis suppressor genes, in 
correspondence with reduced cell migration and invasiveness in vitro; three, genistein 
supplemented diet reduces liver metastasis from colon cancer in athymic nude mice. 
Overall, the results from the current study can facilitate the understanding of molecular 
mechanism behind colon cancer metastasis by investigating the roles of metastasis 
suppressors in the process and the association of genistein exposure and altered 
expression of metastasis suppressor genes.  
 However, in order to provide a sound reference for therapeutic application of 
genistein on colon cancer metastasis, further studies using various timing and dosage of 
genistein exposure will be necessary. Studies have shown that different timing and 
dosage of genistein can have adverse effect on cancer development and progression. For 
example, high dose of dietary soy isoflavone supplementation in older female rats 
increased colon abnormality induced by a carcinogen [160]. However, another study 
showed a gestational and life-long genistein exposure at a lower dose reduces colon pre-
neoplasia in rats [116]. Moreover, the differences between the bioavailability of genistein 
in animals and humans need to be taken into consideration before a biologically safe dose 
can be applied to clinical study. 
In our study, we tried to answer the question whether the primary colon cancer cells 
or the liver microenvironment or both of them affect liver metastasis rate. Our results 
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suggested that molecular signaling in liver microenvironment may play an important role 
in the development of liver metastasis from colon cancer. However, a comprehensive 
study of metabolism and signaling pathway in liver tested at different stage of the study 
in the future could greatly increase our understanding of the molecular mechanism of 
genistein-decreased liver metastasis rate.  
Future study to further investigate the roles of epigenetic alterations in the in vivo 
model, which we established in Chapter 6, need to be conducted to elucidate the 
interactions of colon cancer cells and liver microenvironment, as well as the epigenetic 
regulatory effect of genistein on colon cancer metastasis in vivo.  In addition, extensive 
studies of epigenetic modifications of other metastasis suppressors in the metastasis of 
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